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Human immunodeficiency virus (HIV) is a global health concern that prompts an urgent 
need to develop simple, effective, economical preventive measures. In spite of success 
with current prevention strategies, HIV continues to disproportionately affect men in 
certain sub-populations. The research described in this thesis evaluated the potential for 
topical estriol to induce keratinization of the inner foreskin, the primary site of HIV entry 
in males. My thesis examined the results of a phase 1a clinical trial to determine the 
effects of estriol on the biology of the inner foreskin mucosa. 
Increased keratinization of the vaginal epithelium in monkeys was shown to effectively 
protect against simian immunodeficiency virus (SIV) infection through the female 
reproductive tract. We hypothesized that topical estrogen would have a similar effect on 
the inner foreskin. Using histology, we found that topical estriol can induce keratinization 
of the human inner foreskin by up-regulating the production of keratins per cell without 
increasing skin proliferation. Furthermore, the quantity and position of HIV target cells in 
the foreskin were not adversely affected by the treatment.  
Estrogen receptors (ERs) are transcription factors that are capable of regulating a 
substantial number of target genes when bound by estrogen. Transcriptomic analysis of 
genes differentially affected by our treatment revealed that estrogen primarily acts on the 
keratinocyte epidermal differentiation process. We saw no evidence for an increase in 
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skin proliferation as a result of estrogen exposure. Estriol also induced early differentiation 
of keratinocytes in an immortalized keratinocyte cell line, HaCaT. Taken together, our 
results suggest that treatment of the inner foreskin with estrogen increases keratin 
production in keratinocytes without affecting cellular proliferation. While some adverse 
effects of the treatment were observed, the results of our phase 1a clinical trial were vastly 
positive. We recommend the continuation of this line of study with a larger scale clinical 
trial to determine the long-term effects of treatment. Similarly positive results could have 
a global impact as they imply that treatment provides a safe, cheap, non-invasive method 
for reducing the transmission of HIV while simultaneously aiding in controlling the spread 
of human papillomavirus (HPV).
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Chapter 1 
Introduction
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1.1 Overview 
Human immunodeficiency virus (HIV) is a significant global health concern that continues 
to devastate communities over 30 years after its discovery, in spite of extensive research 
in prevention and treatment. Over 2 million people became newly infected with the virus 
in 2013 [1]. In 2011, men accounted for about 75% of all new diagnoses in the United 
States [2]. Research suggests that in males the primary entry point of HIV virions is 
through the inner foreskin of the penis which contains a dense population of Langerhans 
cells (LCs), a subset of specialized immune cells that act as our body’s first line of defense 
against invading viruses [3, 4].  LCs are highly efficient in degrading HIV in the absence 
of a direct infection with high concentrations of HIV [5]. 
  
In males, the foreskin protects the internal environment from outside forces. The outer 
foreskin has a thick keratin layer that provides a barrier against viral pathogens, thereby 
acting as a safeguard to the LCs. The inner foreskin is characterized by a thin keratin 
layer that yields little protection for the underlying cells [6]. Surgical removal of the foreskin 
(circumcision) provides at least 50% reduced risk of infection [7-9] presumably due to the 
removal of the LCs and the mucosal tissue. Unfortunately, implementing circumcision in 
developing countries that have high infection rates is challenging, particularly in 
populations where it may be culturally or religiously unacceptable [10]. Therefore, there 
remains a critical need to identify countermeasures for preventing HIV transmission that 
are simple to implement, acceptable, economical, readily available, and applicable for 
long-term usage. 
 2 
 
One potential HIV intervention, and the topic of this thesis, is the use of topical estrogen 
to enhance keratin production of the inner foreskin epithelium. Estriol, the weakest 
naturally occurring estrogen, is highly effective in preventing simian immunodeficiency 
virus (SIV) transmission across the vaginal epithelium (an analogous mucosal epithelium 
to the inner foreskin) in monkeys [11, 12]. However, excess estrogen in women can 
increase the risk of breast, uterine, and cervical cancers [13-16]. The foreskin epithelium 
is characterized by the presence of stratified squamous cells as is the vaginal epithelium 
[6]. To date, very few studies have evaluated how foreskin biology is affected by 
estrogens. The work in this thesis examined the structural, cellular, and molecular effect 
of estriol treatment on the physiology of on a subset of epithelial cells, including HIV target 
cells, of the inner foreskin using in vivo and in vitro models. We have demonstrated that 
the human inner foreskin can respond to topical estriol by increasing epithelial and keratin 
thickness. This effect, in turn, may decrease susceptibility to HIV infection by reducing 
HIV virion penetration of the skin and presentation to the underlying target cells. Our 
proposed intervention could help control HIV spread in developing countries using a non-
invasive procedure and may also aid in reducing the incidence of human papillomavirus 
(HPV). Our research supports the potential benefit of using topical estrogen in a phase 2 
clinical trial to assess the efficacy of estriol applied to the inner foreskin in reducing the 
risk of HIV infection. 
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1.2 Skin 
Anatomy and Function 
Skin, the largest organ of the body, is responsible for protecting internal structures from 
the external environment [17]. Among its many important functions, the skin regulates the 
passage of water and other molecules into and out of the body, while simultaneously 
protecting against pathogens, toxins, and injury [18, 19]. The skin is typically divided into 
three layers (Figure 1.1). The subcutaneous tissue, also known as hypodermis, is the 
base layer of the skin and is composed of fat and connective tissue. It provides an energy 
reserve, insulation, and cushion. Above it lies the dermis, which also contains connective 
tissue, giving strength and elasticity to the skin. The epidermis is the outermost layer and 
serves as a waterproof barrier for protection. It is this layer of skin that will be the focus 
of this project. 
 
The protective nature of the epidermis can be attributed to its ability to continuously shed 
and replace its structural cells as they age. These structural cells, keratinocytes, are the 
most abundant cells in the epidermis [20]. As keratinocytes divide, they migrate upward 
toward the surface of the skin forming four layers: the stratum basal, the stratum 
spinosum, the stratum granulosum, and the stratum corneum (Figure 1.2). Epidermal 
keratinocytes maintain the integrity of the skin by producing keratins, a family of structural, 
water-insoluble proteins [21]. Keratins assemble into bundles of intermediate filaments 
consisting of a specific combination of type I (acidic) and one type II (neutral/basic) keratin 
proteins to provide mechanical strength [22]. Each layer of the skin can be characterized 
by the keratin pairs being expressed.  
 4 
 
Figure 1.1 Layers and structures of the skin. There are three layers of the skin: epidermis, 
dermis, and subcutaneous tissue (hypodermis). The skin is comprised of many structures 
that carry out important functions in each layer. 
  
 
  
http://philschatz.com/anatomy-book/resources/501_Structure_of_the_skin.jpg 
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Figure 1.2 Human mucosal (thin) epithelium and full thickness skin. The epidermis of thin 
skin is narrower than thick skin, therefore the stratum corneum is thinner and less 
organized. 
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Keratinocytes in the stratum basal are stem cells that divide mitotically to produce two 
identical daughter cells. One daughter cell stays in the stratum basal to constantly renew 
keratinocytes, while the other migrates up toward the stratum spinosum and begins to 
terminally differentiate (Figure 1.3). Skin-specific keratin proteins 5 and 14 are expressed 
in the mitotically active basal cell layer where they play a role in cell proliferation [23].  
During the process of epithelial differentiation, expression of keratins 5 and 14 decreases 
and cells begin to express a different set of skin keratins, 1 and 10 [20]. As the cells age, 
they begin to flatten, the nucleus and cytoplasmic organelles disappear, and transcription 
ceases. The dying cells become cornified as keratin protein is incorporated into longer 
keratin intermediate filaments. These keratin filaments make up the fully differentiated, 
outermost layer of the skin, the stratum corneum. The dead cells containing the keratin 
are called corneocytes and are constantly replaced as they continuously slough off the 
surface of the skin in a process known as desquamation. Throughout this dissertation, 
this region of the skin may be referred to as the keratin layer or the stratum corneum. 
 
During skin development, keratin protein production may be up-regulated in response to 
wound healing and disease. For example, keratins 6 and 16 are normally expressed in 
hyperproliferative stratified epithelia or epithelia with abnormal differentiation. In normal 
stratified epithelia, only basal levels can be detected [24]. Following injury, expression of 
keratins 6 and 16 is up-regulated and maintained during the repair process [25-27]. In 
addition to the keratin proteins, there are other specialized proteins in the skin that are 
responsible for adhering keratinocytes within the epidermis and supporting the structure 
of the stratum corneum (Figure 1.4). 
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Figure 1.3 Creating a protective barrier through keratinocyte differentiation. Daughter 
cells of proliferating keratinocytes (epidermal stem cells) move out of the stratum basal 
and migrate up toward the stratum spinosum. As the cells undergo terminal differentiation, 
they lose their nucleus and begin to flatten. These flattened keratinocytes comprise a 
network of dead cells in the stratum corneum that are linked together with junction 
proteins and lipids.  
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Figure 1.4 Genes critical to the differentiation process. Keratin expression is specific to 
the stage of cell differentiation. As cells begin to differentiate, expression of the 
proliferating keratin pair (K5/14) is down-regulated, as expression of the differentiating 
keratins (K1/10) is up-regulated. The differentiation process is further characterized by 
the expression of keratin binding, crosslinking, and cornified cell envelope precursor 
proteins. 
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Hemidesmosomes are cell adhesion structures that bind keratinocytes to the basement 
membrane of the epidermis, while desmosomes link keratinocytes together [28, 29]. 
Filaggrin binds to keratin to aid in the aggregation of the keratin filaments, thereby 
providing additional structural support to the stratum corneum [30]. Involucrin, a protein 
synthesized during terminal differentiation, aids in formation of an insoluble envelope, by 
crosslinking to membrane proteins [31]. As the outer surface of the epithelium comes in 
contact with harsh conditions from the external environment, the cornified cell envelope 
serves as a major contributor to the epithelial barrier protecting the inner surface of the 
skin [20]. 
 
The expression of the aforementioned genes that are involved in the formation of the 
cornified envelope, such as the keratins, filaggrin, and involucrin, have been extensively 
studied in cell culture. HaCaT (human adult skin keratinocytes propagated under low Ca2+ 
conditions and elevated temperature) cells,  immortal, nontumorigenic keratinocytes, are 
a common keratinocyte cell line used  to study proliferation and differentiation [32]. Their 
growth pattern in culture is similar to normal human keratinocytes in vivo, so they are 
commonly used to study skin response to various stimuli. To determine what effect the 
stimulus has on the skin, the normal condition of the skin must be taken into consideration. 
 
1.2.1 Foreskin anatomy, physiology, and immunology 
Skin covers the entire body and is contiguous with the mucous membrane of the genitals 
[6]. Although males and females have distinct reproductive physiology, the prepuce is an 
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external genitalia tissue that is inherent to both male and female anatomy. The prepuce 
forms the clitoral hood of the female genitalia, while its counterpart in males is the 
foreskin. The foreskin is comprised of two distinct layers: the outer and the inner [6] 
(Figure 1.5). The outer foreskin, an extension of the skin covering the penile shaft, serves 
as a protector of the glans penis (the head of the penis) and the inner foreskin [6]. The 
inner foreskin is a mucosal epithelium that forms an interface with the outer foreskin and 
the glans penis. It functions as a barrier against moisture loss as well as infection with 
pathogens and harmful agents. This region of the foreskin is characterized by a thin layer 
of keratin covering the underlying tissue [33]. Keratin aids in protection from exposure to 
external environmental conditions. When the outer foreskin is folded over the inner 
foreskin (as in the flaccid state) a moist environment is formed which aids in protection of 
the glans penis from the external environment [6].  
 
In addition to this physical barrier, the foreskin plays an important role in the innate 
immune system. The foreskin epithelium is thought to be the main site of HIV entry into 
the penis, presumably because it is densely packed with Langerhans cells (LCs) [34]. 
LCs, derived from bone marrow, are a subset of dendritic cells that survey the epithelium 
for foreign antigens. They are capable of recognizing and engulfing pathogens like viruses 
present on the cell’s surface through endocytosis [35]. Upon internalization, the pathogen 
is degraded and a fragment of the antigen is displayed on the outer surface of the cell 
[36]. LCs present the antigen to the T-cells to elicit an immune response [37, 38]. In 
addition LCs express cytokine and chemokine receptors that aid in innate and adaptive  
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Figure 1.5 Retraction of the outer and inner foreskin. The foreskin is attached to the penis 
at the frenulum. In its relaxed state, the penis is fully or partially covered by the outer 
foreskin (thick skin). During an erection, the outer foreskin is retracted exposing the inner 
foreskin (thin skin). When the male has sexual intercourse with an HIV infected partner, 
the inner foreskin is presumably the site where the virus enters the body.  
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immune responses. LCs are present in all epithelial tissues throughout the body, but are 
more concentrated in the mucosal epithelia (foreskin, vagina, mouth, anus etc.) most 
likely due to the increased level of exposure to microbes than other skin [39]. Being in 
close proximity to the thin, mucosal layer of the inner foreskin renders LCs susceptible to 
infection by viruses and other infectious agents, which can result in disease [40] (Figure 
1.6). Viruses cannot survive for long periods of time outside of a host cell. The foreskin 
may create a permissible environment for infection, particularly when the penis returns to 
the relaxed state after a sexual encounter with an infected partner. The warm, moist 
environment favors survival of viruses, therefore, many infectious agents are commonly 
transmitted during unprotected sexual intercourse. Human immunodeficiency virus (HIV) 
is a well-studied sexually transmitted viruses that cannot be cured. The prevention of this 
viral infection is of utmost importance in many communities.  
 
1.3  HIV  
Human immunodeficiency virus (HIV) has infected over 75 million people and caused 
over 35 million deaths worldwide [41], making it one of the greatest health crises in human 
history. There is a desperate need to develop simple and effective strategies to prevent 
HIV infection. Attempts to combat the disease are taking place on many fronts, from the 
development of HIV vaccines to the therapeutic use of microbicides, prophylactics, and 
extensive sexual education programs. However, there have been very few breakthroughs 
in these areas and we are far from being able to control the epidemic by any of these 
means.  
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Figure 1.6 Langerhans cell near the apical surface of the epithelium. Langerhans cells 
survey the inner surface of the skin with their dendritic arms to detect the presence of 
pathogens. These cells are capable of engulfing and degrading foreign material through 
specialized receptors and compartments with subsequent antigen presentation to T-cells 
circulating in the lymph nodes. 
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In the early 1980s, there was a sudden surge in male patients presenting with severe 
pneumonia, sudden weight loss, and in some cases, a rare cancer called Kaposi sarcoma 
[42-44]. Over time, these men experienced a decline in the function of their immune 
system. These symptoms along with opportunistic infections that were seen in this patient 
population were categorized as acquired immunodeficiency syndrome (AIDS). It was not 
long before scientist discovered that HIV was the virus that caused this illness. HIV is an 
enveloped, retrovirus with an RNA genome [42]. The envelope contains glycoprotein 
spikes that are essential for the attachment of the virus to the host cell [45]. Untreated 
HIV develops into AIDS when the virus destroys essential immune cells responsible for 
initiating the body’s response to infection called CD4+ T-cells [46]. The virus can only 
infect cells displaying a specific combination of receptors, a main receptor, CD4, and a 
co-receptor [47] (Figure 1.7). The co-receptor varies depending upon the target cell, but 
the two major types are CCR5 and CXCR4 [47]. Both receptors are expressed on cells 
that play an essential role in the immune response to viruses. CCR5 is the predominant 
co-receptor targeted in HIV transmission and is mainly expressed on dendritic cells and 
macrophages, while CXCR4 tends to be associated with T-cells [48-51]. Once the virus 
successfully enters the host cell, it highjacks the cell’s transcriptional machinery to make 
copies of itself [52]. These new virus particles are released from the cell, spreading and 
infecting nearby cells. As cells become damaged, the decline in the number of functioning 
CD4+ cells results in a weakened immune system that is more susceptible to secondary 
infections [53]. 
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Figure 1.7 HIV Co-receptors. The HIV protein, env, is made up of glycoproteins gp120 
and gp41 that are required for viral entry into the cell. Binding of gp120 to CD4 induces a 
conformational change, allowing the virus to bind to the co-receptor CCR5 on 
macrophages or CXCR4 on T-cells.  
 
 
  
Modified from Frontiers in Bioscience 3, d44-58, January 1, 1998 
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As HIV multiplies and spreads throughout the body, it can be transmitted to other people 
through direct contact with body fluids such as blood, semen, or vaginal secretions [54]. 
However, it cannot survive very long outside of the host [55]. In order to establish 
infection, the virus must complete a six-step process that is described in brief here [56]. 
To enter a host cell, the virus must bind to CD4 and a co-receptor. Once the virus enters 
the cell, reverse transcriptase will convert the RNA genome to DNA. The viral DNA may 
integrate into the host cell’s DNA. During new synthesis, the viral DNA is transcribed into 
mRNA, which is translated into one long polypeptide. Protease cleaves the polypeptide 
into individual viral proteins that make up the virion: spikes, capsid and reverse 
transcriptase. New viruses are assembled and released from the cell to infect more cells. 
Each step is a potential target for drug therapy to prevent the replication and spread of 
HIV.  
 
1.3.1 Current Prevention Strategies 
Although, HIV is a devastating disease, survival rates have continuously improved in 
recent years due to the advancement in the development of effective treatments. There 
have been a handful of cases in which HIV patients have been “cured” of the disease by 
eliminating the viral reservoirs in the body.  
 
In one study, a baby born to a HIV infected mother was given immediate and aggressive 
treatment with an anti-HIV drug regimen called highly active anti-retroviral therapy 
(HAART) [57]. HAARTs success is primarily due to its employment of a combination of 
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drugs to block several steps of the viral replication cycle, reducing the likelihood of drug 
resistance. However, there are many adverse effects of these medications which can lead 
to non-compliance and misuse of the drugs. Soon after the treatment began, examination 
of the baby’s blood confirmed that the virus had been transmitted to the baby during birth.  
One month after the baby was born, HAART treatment had been successful at lowering 
the levels of HIV below the detection limit.  After adhering to the HIV regimen for at least 
15 months, the mother began to miss medical appointments and reported discontinuing 
the use of the ARTs when the baby was 18 months old. When the mother resumed 
medical care for the baby at 23 months, the doctors were unable to detect HIV RNA or 
antibodies in the baby’s blood, despite being off of medication for about 5 months [57]. 
Sadly, recent news reports indicate that after being off of medication for 27 months, the 
child has again tested positive for the disease [58].  
 
In another case, an HIV infected patient taking ARTs who also had acute myeloid 
leukemia was given a bone marrow transplant from a donor who was CCR5 negative [59]. 
The patient continued with his ART regimen up to the day before his transplant. Twenty 
months after the transplant and no ART treatment, the patient had no detectable levels 
of the virus [59]. Both of these cases were unique as they were instrumental in 
demonstrating that HIV can be reduced to undetectable levels after establishing infection.  
 
HIV is still considered an incurable infection, and even the best treatment will only delay 
the progression of HIV to AIDS. In addition treatments like those described above are 
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very expensive and largely inaccessible to areas where HIV/AIDS has become endemic. 
Controlling the increasing rates of infection in susceptible populations rely on preventing 
exposure to the virus through abstinence, monogamy, and most importantly, using 
prophylactics [60]. I choose to live by the mantra, “prevention is better than a cure.” As 
such, the research project detailed in this paper focuses on a novel method to potentially 
prevent transmission of HIV. 
 
1.3.3 Circumcision 
Efficient means for reducing new HIV infections should prevent or reduce transmission of 
the virus. To date, the most significant advance in HIV/AIDS prevention has been the 
surprising correlation of circumcision and a reduced risk for HIV infection. Circumcision 
began in ancient Egyptian times as a ritualistic practice but is currently performed as a 
cosmetic and/or hygienic practice in Western cultures [61, 62]. It is a common medical 
procedure in which the foreskin is surgically removed from the glans penis [63]. It is well 
known that there are many benefits to circumcision, including lower risks of urinary tract 
infections [64], penile cancer [65], and some sexually transmitted infections [66-68].  In 
September 2012, the American Academy of Pediatrics published its circumcision policy 
stating that the potential health benefits of circumcising newborn males outweigh the risks 
associated with the surgical procedure [69]. 
 
The results of three large randomized trials of male circumcision, carried out in Kenya [7], 
Uganda [8], and South Africa [9] leave no doubt that circumcision more than halves a 
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man’s risk of HIV infection [70, 71]. The protective effect is thought to be due to the 
physical removal of most of the foreskin epithelium containing HIV target cells [34, 72]. 
Removal of the foreskin, the primary site of HIV infection in men, through circumcision 
results in keratinization of the remaining epithelium covering the glans penis. This may 
confer a level of protection against infections with external pathogens [6].  
 
While male circumcision is undoubtedly effective in reducing the risk of male HIV 
infection, implementing such a surgical preventative strategy is a daunting task, 
particularly in countries like India, China and most of South-East Asia where circumcision 
may be culturally unacceptable [73]. In addition, a circumcision program requires 
extensive medical training, personnel, and equipment. Studies suggests that the 
populations who would most benefit from the protective effect of circumcision may be 
high-risk populations (e.g. sex workers, men who have sex with men, and drug users) 
and female to male transmissions due to lower rates in the general population [74]. Other 
interventions will likely be required in these populations and those with high rates of HIV 
infection to control its spread. Male to female transmission tends to be the primary mode 
of transmission for new infections, so preventative methods need to be explored in this 
populations as well [75]. Rather than removing the LCs by circumcision, another method 
to prevent infection would be to create a barrier to reduce the exposure of the LCs to the 
virus.  
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Many researchers are studying the potential of microbicides as an effective means of 
preventing the spread of sexually transmitted diseases. Microbicides reduce infection in 
a number of ways by creating a physical barrier that keeps HIV and other microbes from 
reaching target cells and thereby preventing replication within the cell [76-78]. Although 
microbicides can been produced in many forms, most have been developed for the vagina 
and the rectum just before intercourse.  Unfortunately, this limits protection to women and 
men who have sex with men [79]. Additionally, these regions of the human anatomy are 
subject to micro tears during sexual intercourse, providing direct access of the virus to 
the circulatory system [80]. An ideal microbicide would be one that can be applied at any 
time prior to the sexual encounter. There is a need to explore additional effective means 
of preventing disease.  
 
1.4  Estrogen 
Estrogens are essential in the development and maintenance of reproductive tissues. In 
addition, they have multiple targets so their biological effects are widespread throughout 
the body. Because estrogens are capable of regulating the activity of distal organs and 
tissues, they can also affect the activity of the cardiovascular, musculoskeletal, immune, 
and central nervous systems [81]. There are three major forms of natural estrogen 
produced by the body [82]. The most potent form, 17β-estradiol (E2), is the predominant 
estrogen found in the circulation of reproductive aged women. When a woman becomes 
pregnant, she begins to secrete higher levels of estriol (E3), the weakest of the three 
forms [82]. When a woman reaches menopause, estrone (E1) becomes the primary form 
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of circulating estrogen [82]. Men also produce estrogen, although at much lower levels 
than women [83].   
 
1.4.1 Mechanism of Action 
Estrogens can diffuse across the outer cell membrane and carry out their action in the 
cytoplasm and nucleus [84]. The biological effects of estrogen are mediated through two 
cytoplasmic estrogen receptors (ER), estrogen receptor alpha (ESR1) and estrogen 
receptor beta (ESR2). When the ERs are bound by their endogenous hormones, they 
become activated and the newly formed complex translocates to the nucleus where it 
regulates transcriptional activity of many genes, often resulting in increased proliferation 
of cells [85]. All estrogens have an affinity for the ER, however, E2 exhibits the strongest 
relative binding affinity followed by estriol, and lastly, estrone [86]. Estrogen signaling can 
occur through genomic or non-genomic actions (Figure 1.8).  The classical genomic 
signaling pathway takes place inside of the cell when the estrogen-estrogen receptor 
complex binds to specific DNA sequences called estrogen response elements (EREs) in 
the promoter of target genes to regulate gene expression [87]. Alternatively, ERs can also 
regulate gene expression without directly binding to DNA, through protein-protein 
interactions with DNA-binding transcription factors in the nucleus [82]. Genomic signaling 
may take hours or days to produce an effect, while, rapid responses are usually due to 
non-genomic signaling initiated at the cell membrane.  Here, the ER interacts with 
signaling molecules, activate signal transduction pathways, which could affect the 
transcription of genes that lack EREs in their promoters [88]. The ultimate action of 
estrogen depends on its target tissue. The main targets are the female reproductive tract,  
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Figure 1.8 Genomic and non-genomic actions of estrogen. Estrogen diffuses into the cell 
and acts on its receptors to activate or repress transcription of target genes. Estrogen can 
also bind to receptors on the cell membrane to exert non-genomic effects through signal 
transduction. The latter mechanism induces rapid changes in gene expression. 
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however, estrogen also acts on many organs including the brain, bone, liver and heart 
[89]. Estrogen has significant effects, positive and negative, on skin biology, including the 
modulation of epidermal keratinocytes [90].   
 
Estrogen decreases the amount of time needed for wounds to heal [91, 92]. Topical 
administration of estradiol increases epidermal thickness, presumably by inducing 
keratinization [93, 94]. It is well known that estrogens can stimulate uterine epithelial 
proliferation [95-97]. In addition, the hormone is used to improve inflammatory conditions 
that affect both women and men, such as vaginal atrophy and phimosis [98, 99]. Vaginal 
estrogen cream or tablets are widely used by postmenopausal women to treat vaginal 
atrophy by thickening and keratinizing the vaginal epithelium [100, 101]. There is a well 
demonstrated link between the vaginal epithelial structure and its susceptibility to HIV 
infection. The vaginal epithelium contains a high density of LCs and, as in the foreskin, 
the LCs are thought to be the primary site of HIV entry into the female reproductive tract 
[102]. Furthermore, an European study evaluating HIV-1 discordant couples found that 
women over the age of 45 had a 4-fold higher risk of acquiring HIV than their younger 
counterparts [75]. Thus, the thinning of the vaginal epithelium as a result of a decline in 
estrogen levels after menopause may contribute to this increased risk [103].   
 
To study how estrogen affects the susceptibility of the vaginal epithelium to HIV infection, 
ovariectomized Rhesus monkeys were treated with either intravaginal estriol or a placebo 
base cream and then challenged intravaginally with simian immunodeficiency virus (SIV) 
 24 
 
[11]. Estriol treated animals showed a dramatically increased resistance to SIV infection; 
only one of the twelve estriol treated animals became infected when challenged with SIV, 
compared to six of the eight ovariectomized controls treated only with placebo [11]. The 
estriol treated animals all became infected if the SIV was injected beneath the vaginal 
epithelium, showing that the resistance to infection was occurring at the epithelial surface. 
The increased keratinization of the vaginal epithelium induced by the topical estriol 
treatment is hypothesized to have reduced the number of SIV virions coming into contact 
with the LCs, thus preventing infection. Despite the strong protective effect of estrogen in 
these ovariectomized monkeys, the same response was not observed in animals with 
intact ovaries and normal cycling hormone levels. Moreover, the vagina is frequently 
subjected to trauma during intercourse causing tears in the epithelial lining [104], negating 
any protective effect of an increased keratin thickness through the use of topical estriol 
treatment. Finally, and perhaps most importantly, estrogen is a known co-factor in many 
vaginal and cervical cancers and its long-term administration to the vagina would be 
inadvisable making this intervention unlikely to be of use in humans for reducing the 
susceptibility of women to HIV [16].  
 
1.5 Scope of Thesis 
Our studies propose to validate topical estrogen as a medical alternative to circumcision 
to aid in the reduction of HIV transmission in uncircumcised men. While the role of 
estrogen in regulating epithelial keratinization in women is well established, comparable 
studies in men have not been well documented. The preputial mucosa of the male inner 
foreskin is an analogous mucosal epithelium to that of the vagina, with a very thin layer 
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of overlying keratin [33]. However, unlike the vagina, the foreskin has a lower risk of 
trauma during intercourse, and it is not exposed to significant levels of systemic hormone 
cycling. A number of prior studies have utilized the epithelium modifying properties of 
estrogen to treat phimosis (a constriction of the foreskin preventing its complete 
retraction) in children, adolescents and adults [99, 105]. Estrogen treatment was effective 
in reversing foreskin constrictions in the vast majority of cases. Estrogen is very effective 
in increasing moisture and collagen content of the skin, leading to its increased elasticity 
as well as increasing keratin thickness [106]. The increased elasticity of the foreskin 
caused by such treatments (in addition to the keratin increase) could also be beneficial to 
controlling HIV as it would reduce the likelihood of foreskin sustaining micro tears or 
epithelial breakage during intercourse. Several studies of transgender males as well as 
children given topical estrogen to treat foreskin infections reported negative side effects 
of high estrogen treatment. However, these side effects are usually reversible upon 
cessation of the treatment [99, 107]. These findings support the need to determine 
minimal doses of weak estrogenic compounds to avoid any adverse systemic estrogenic 
side effects of topically applied estrogen in males.   
 
As most studies were performed over a short time period, there is still a need to examine 
the effect of chronic treatment in men. We propose the use of estriol since it is a weak, 
naturally occurring estrogen metabolite that is normally present in human male urine, and 
is thus unlikely to cause hypothalamic inhibition or gynecomastia at low levels. To support 
this statement, studies have been performed to assess the systemic effect of topical 
estrogen treatment. Luteinizing hormone is responsible for stimulating the production of 
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estrogen [108]. Similar treatment regimens to those proposed in our study have been 
assessed in women and were shown to have no effect on circulating luteinizing hormone 
(LH) concentrations indicating no systemic effects from the treatment and only a local 
response [109]. Pask et al. has previously examined the ability of topical estrogen to 
increase keratin production of the inner foreskin epithelium [110]. Their results showed 
that topical administration of estriol (Ovestin cream, 1mg/ml, Organon) for 14 days, 
caused a rapid and sustained increase in inner foreskin keratinization (similar to the 
estrogen response observed in the vagina). However, contact smears only provide an 
indirect examination of keratinization of the foreskin, therefore a more direct means of 
examining this phenomenon is needed. The studies mentioned above assessing the 
response of the vaginal epithelium of Rhesus monkeys to estrogen reported a similar 
keratinization response to that induced by estriol in men after 74 days of estradiol 
treatment [11]. Although that study used a more potent form of estrogen, we hypothesized 
that small amounts of topically applied estriol would be sufficient to induce an increased 
keratin thickness on the foreskin without yielding any measurable systemic effects. 
 
While the primary effect of estrogen on the thickness of the epithelium in humans has 
been documented, how it affects foreskin biology and particularly susceptibility to virus 
infection, is less well-understood. This will be thoroughly investigated in Chapters 2 and 
3 of this thesis. The foreskin, like the vagina and most other epithelial surfaces, contains 
a high density of estrogen receptors, necessary for transducing the estrogen signal and 
affecting gene transcription. Estrogen acts as a mitogen in the skin, stimulating the 
proliferation and decreasing terminal differentiation of keratinocytes under stressful 
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conditions such as wounding or infection [111-113]. This in turn results in increased 
thickness of the stratum corneum. Estrogens have also been shown to affect Langerhans 
cell maturation and antigen presenting capacity [114]. Macrophages treated with estrogen 
display decreased migratory capacity and increased apoptosis [115]. Estradiol has also 
been shown to affect HIV target cells through their estrogen receptors and to regulate the 
expression of HIV-1 receptor molecules, and the release of chemokines and cytokines 
[114]. The estrogen receptors themselves are widely distributed in multiple layers of both 
the epidermis and dermis as well as on LCs and macrophages. Treatment of 
ovariectomized mice with estradiol increases CD4+ T lymphocyte expression of CCR5 
[114]. The stratified epithelia of genital tissues are populated by T cells, LCs and 
macrophages, all of which express the CD4, CCR5 and CXCR receptors. In addition, the 
sub-epithelium is densely populated with dendritic cells, T cells and macrophages 
expressing CD4, CCR5 and CXCR4 receptors. Due to the expression of these known 
HIV-1 receptors, immune cells of the epithelium and sub-epithelium are highly susceptible 
to HIV-1 infection. How each of these cell types and their HIV-1 receptor expression 
respond to topical estriol treatment is unknown and must be evaluated before assessing 
the efficacy our proposed intervention. We will characterize how topical estriol mediates 
reduced epithelial susceptibility to viral infection through keratinization and epithelial 
thickening. The aim of this thesis is to determine the role of estrogen in modifying the 
inner foreskin epithelium. I will provide definitive evidence to support the need of a phase 
2 clinical trial to further define estrogen’s role as an adjunct treatment to reduce the risk 
of HIV infection.                      
  
 
 
 
 
 
 
CHAPTER 2 
Elucidating the effect of topical estriol on 
foreskin epithelium
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2.1 Background 
The results of three large randomized trials of male circumcision and its protective effect 
on female-to-male HIV infection, carried out in South Africa [9], Kenya [7] and Uganda 
[8], leave no doubt that circumcision at least halves a man's relative risk of HIV infection. 
The protective effect of circumcision is thought to be due to the physical removal of the 
majority of the inner foreskin epithelium, the main site of HIV entry into the penis [33, 116]. 
The inner foreskin is a mucosal membrane [6] with little overlying keratin. It is richly 
supplied with Langerhans cells, whose dendritic processes lie close beneath the epithelial 
surface. Langerhans cells are a vital part of the body's natural epithelial defense against 
HIV infection since they contain the c-type lectin, Langerin, which can degrade viral 
particles entering the cell [117]. The risk of HIV transmission through non-mucosal skin is 
significantly reduced due to a thicker stratum corneum that forms a physical barrier 
against virion entry [33, 110]. If keratin production in the inner foreskin mucosa could be 
increased to that of non-mucosal skin it could significantly reduce the risk of HIV infection 
in uncircumcised men. In this study, we investigated the use of a topical treatment to 
increase keratin production in the inner foreskin mucosal epithelium.  
 
It is well established that the human vaginal epithelium (a mucosal epithelium containing 
many Langerhans cells [118] that is analogous to the foreskin epithelium) responds to 
topical estrogen administration by thickening presumably as a result of keratinization. A 
decline in estrogen levels in post-menopausal women is associated with vaginal atrophy 
and a four to eightfold increased risk of HIV infection compared to premenopausal women 
[75, 119]. The protective role of the estrogen exposed epithelium in preventing HIV 
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infection was verified in a series of experiments in Rhesus monkeys. Monkeys were 
ovariectomized to remove endogenous estrogen production and then treated 
intravaginally with topical estriol or a control base cream. Following the treatment 
regimen, both groups were given an intravaginal challenge with an inoculum of simian 
immunodeficiency virus (SIV) [11]. Only one of the twelve treated animals became 
infected, compared to six of the eight untreated controls (p=0.0044). However, estrogen 
treated animals did become infected if the SIV was injected sub-epithelially, showing that 
the resistance to infection was occurring at the epithelial surface [12]. Thus, the increased 
thickness of the vaginal epithelium’s stratum corneum induced by the topical estrogen 
produced an effective barrier to prevent infection. 
 
The majority of estrogen action is mediated via the estrogen receptors (ERs) alpha and 
beta. We have previously reported that both ERs are abundant in the human inner 
foreskin and respond to topical estrogen [110]. Furthermore, treatment accelerated the 
rate of keratinization of the inner foreskin. However, this study was limited to two 
participants and keratinization was only assessed using the indirect measure of 
determining the amount desquamated keratinocytes from the inner foreskin. Despite its 
limitations, this preliminary study suggested that the foreskin could elicit an increase in 
keratin production and thicken the stratum corneum similar to what has been observed in 
the vaginal epithelium, following topical application of estriol [11, 120]. As such, the 
foreskin’s natural barrier to viral entry could be enhanced.  
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We have determined the effects of topical estrogen on inner foreskin biology using a low 
dose of the naturally occurring and weak estrogen metabolite, estriol. Estriol was chosen 
to reduce the risk of any adverse systemic side effects such as gynecomastia or infertility 
observed with high dose or long-term exposures.  Lutenizing hormone (LH) is known to 
stimulate estrogen production in women. Similar estriol treatment regimens to those used 
in this study had no effect on circulating LH concentrations, suggesting that the treatments 
are unlikely to have systemic side effects [121]. In addition, a significant keratinization 
response was detected in the vaginal epithelium of Rhesus monkeys using as little as 25 
µg of estriol applied twice weekly [11].  
 
Here, we report the results of a phase 1 clinical trial (clinical trial number H2007/02979) 
examining the response of the foreskin to topical estrogen by performing a direct 
assessment of stratum corneum thickness in vivo both pre- and post-treatment. We 
sought to determine the minimal effective dose needed to induce keratinization of the 
stratum corneum. Since estrogen has also been reported to affect Langerhans cell 
maturation and migration [122], we also examined how estrogen affected Langerhans cell 
density and depth in the inner foreskin epithelium. Our findings show that topical estriol 
is able to induce a significant increase in the thickness of the stratum corneum without 
altering the Langerhans cell number or distribution. 
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2.2 Methods 
Study Participants  
Twenty-five adult men aged 24-65 scheduled for elective circumcisions at the Urology 
Clinic at the Austin Hospital in Melbourne, Australia were recruited to participate in the 
study. Eligibility criteria for the study was: (1) male; (2) aged 18 and above; (3) already 
scheduled for elective circumcision; (4) acceptable condition of the foreskin tissue based 
on the surgeon’s assessment of medical history and the presenting condition. Study 
exclusion criteria included severe balanoposthitis/ phimosis and unacceptable foreskin 
condition, based on the surgeon’s assessment at the time of recruitment and the patient’s 
medical history. All participants signed an institutional review board approved consent 
form declaring their willingness to participate in the trial.  
 
Study Design 
The participants provided a 3mm standard punch-hole biopsy taken from the inner 
foreskin before treatment began (hereafter referred to as the pre-treatment biopsy) to 
establish a baseline of their individual keratin thickness before treatment. The men were 
then randomly assigned to one of 5 groups to determine minimal dose; placebo (base 
cream without estriol) or an identical base compound, commonly used as an ointment 
base, containing estriol as an active ingredient in varying concentrations (500 µg, 50 µg, 
25 µg, or 12.5 µg; each diluted in 0.5ml of base cream) for fourteen days prior to 
circumcision (Table 2.1). Specific dose concentrations were blinded from the participants,  
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Table 2.1 Randomized Treatment Group Assignments. 
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the consulting surgeons, and the research team until all data had been collected. To 
produce the desired concentrations for each treatment group, estriol (Sigma-Aldrich, 
Sydney, Australia) was diluted in 0.5ml of the base cream Cetomacrogol (Skin Basics, 
Laverton North, Australia), which was mixed with a small amount of liquid paraffin (David 
Craig, Laverton North, Australia). The cream was supplied to participants in preloaded 
1ml plastic disposable syringes, marked for each day of administration so that an accurate 
dose would be applied. Participants were asked to return all syringes (used and unused) 
at the conclusion of the trial to track compliance. The procedure for application of the 
cream was as follows: 1.) Uncap a pre-filled single-dose applicator. 2.) Holding the 
applicator in one hand, pull back the foreskin with the other. 3.) Apply the cream to the 
exposed inner foreskin by depressing the applicator plunger. 4.) Distribute the cream 
evenly over the entire surface of the exposed inner foreskin using your finger. 5.) Allow 
the foreskin to retract/relax back over the glans. 6.) Place the used applicator in the 
container provided. 
 
At the conclusion of the treatment period (14 days), circumcision was performed using 
the dorsal slit method [123]. Inner foreskin tissues from the dorsal, ventral, and frenular 
regions (Figure 2.1) of the inner aspect of the foreskin were collected using a 5 mm punch 
hole biopsy tool (here after referred to as post-treatment biopsy) and processed to 
determine the effect of treatment on stratum corneum thickness and the number and 
localization of Langerhans cells. All data was compared to patient-matched control pre-
treatment biopsies.  
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Figure 2.1 Dorsal Slit Method for Circumcision.  
a.) A circumferential cut is made on the inner and outer preputial skin slightly above the 
corona. A dorsal slit is made along the foreskin from the tip to the corona.  
b.) The foreskin is removed and the glans penis is permanently exposed.  
c.) Biopsies were collected from dorsal, frenular, and midventral areas of the excised 
foreskin. 
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Tissue Processing 
Tissues were fixed in 4% paraformaldehyde overnight at 4oC, then washed several times 
in cold phosphate buffered saline before paraffin embedding. Eight micron sections of 
each sample were cut and placed onto superfrost-plus glass slides (Fisher Scientific, 
Agawam, MA) for downstream analyses. Twenty slides containing post-treatment tissue 
from each region mentioned above were randomly chosen from a larger batch for analysis 
using a random number generator. Due to the small size of the pre-biopsy sample (3mm), 
twelve sections were selected from each patient for comparison.  
 
Assessment of Stratum Corneum Thickness using the Ayoub-Shklar Staining 
Ayoub Shklar staining [124] was performed to assess the thickness of the stratum 
corneum, the outermost region of the skin made up of corneocytes (dead cells packed 
with keratins). All solutions were freshly prepared and filtered using filter paper prior to 
use in staining protocol. Sections were deparaffinized in Citrisolv (Fisher Scientific, 
Agawam, MA) for a total of 30 minutes and rehydrated with 100% ethanol, followed by 
95% and 70% dilution. Slides were washed in 1xPBS and stained with 5% acid fuschin 
for 3 minutes, then in aniline blue-orange G (Acros Organics, Fair Lawn, NJ) for 45 
minutes. Stained slides were dehydrated with 95% and 100% ethanol, respectively, and 
coverslips were mounted using DPX (CTL Scientific Supply Corp., Deer Park, NY). 
Images were collected using an Olympus BX40 microscope equipped with a Moticam 5 
mega pixel camera and the accompanying Motic software (British Columbia, Canada). 
Each image was examined for keratin accumulation in the stratum corneum by collecting 
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measurements randomly along twelve sites across the intact apical surface of the 
epithelium (Figure 2.2a). The closest distance between the apical and basal edges of the 
stratum corneum were manually measured in µm using Image J software (NIH, Bethesda, 
MD). Over 900 data points were collected per patient. The mean keratin thickness was 
compared between pre- and post-treatment biopsy samples for individual patients as well 
as within and across treatment and control groups. 
 
Assessment of Langerhans Cell Number and Location 
Immunofluorescence was performed to assess Langerhans cell density and distribution 
within the inner foreskin epithelium. Sections were dewaxed, rehydrated, and blocked 
with 10% BSA (Sigma Aldrich, St. Louis, MO, USA). Langerhans cells present in the skin 
and epithelia were identified using a mouse monoclonal anti-human Cd1a antibody (Leica 
Biosystems, United Kingdom). To enhance staining, two secondary antibodies, FITC-
conjugated chicken anti-mouse and FITC-conjugated goat anti-chicken (Abcam, 
Cambridge, MA, USA), were applied consecutively using a 1:100 dilution prepared in 1X 
PBS. Slides were washed with 1X PBS in between antibody applications. To visualize the 
nuclei, 4',6-Diamidino-2-Phenylindole (Dapi, Invitrogen, Carlsbad, CA, USA) was applied 
to each section. Each slide was cover slipped using Prolong Gold antifade reagent 
(Invitrogen, Carlsbad, CA, USA) to preserve the fluorescent signal during long-term 
storage. Images were captured using DeltaVision RT Systems with SoftWorx software 
(Applied Precision, Issaquah, WA).  Seventy-two sections of foreskin per patient were 
evaluated to determine the number of Langerhans cell within the epithelium in a field of  
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Figure 2.2 Histological staining of the inner foreskin. 
a.) Ayoub Shklar (AS) staining of inner foreskin tissue (top panels). AS differentially stains 
keratin and pre-keratin. The stratum corneum (keratin layer) is stained red; the stratified 
squamous epithelium is gray; the stratum spinosum (pre-keratin) is orange; the 
connective tissue is blue; erythrocytes are red. Keratin thickness was randomly measured 
at six sites across the intact epithelial keratin layer  
b.) Immunofluorescence staining for Langerhans cells in inner foreskin tissue using CD1a 
antibody (bottom panels). CD1a (green) was used to identify Langerhans’ cells present 
throughout the epithelium. DAPI (blue) was used to counterstain nuclei. Yellow lines 
indicate measurement of Langerhans’ depth within the cell. Langerhans’ cell projections 
can be seen as green staining not associated with a nucleus (yellow arrow head in inset. 
Inset shows Langerhans cell in the inner foreskin at 100X magnification.  
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view and the distance of the cell from the apical surface (Figure 2.2b). Cells were 
manually counted and the density per mm2 determined using Image J (NIH, Bethesda, 
MD) was tabulated in Microsoft Excel. To determine the depth of the cells, the distance 
of the Langerhans cell nucleus to the apical surface of the epithelium was manually 
measured in µm using the straight line tool in Image J (NIH, Bethesda, MD). 
 
Statistical Analyses 
A Welch’s t-test was performed to compare the mean Langerhans cell density and depth 
between pre and post treatment samples for each individual. GraphPad InStat version 
3.10 for Windows (GraphPad Software, San Diego, CA) was used to analyze the mean 
keratin thickness of the stratum corneum. Since initial assessment determined that the 
data was non-parametric, the Kruskal-Wallis test (a non-parametric equivalent of 
ANOVA), was performed to determine the percentage change between baseline and 
post-treatment within each treatment group. Bonferroni correction was used to control the 
family-wise error rate. Dunn's Multiple Comparisons test was used post analyses to 
determine which specific group means differed. A p-value of less than 0.05 was 
considered statistically significant. 
 
2.3 Results 
Twenty-five adult men participated in the study, however, due to concerns with proper 
consent, the data reported here is for only 20 of the patients. We analyzed inner foreskin 
samples collected from twenty adult men scheduled for elective circumcision. Sixteen 
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patients received active hormone therapy; 5 in the 500 µg estriol/day cohort (Group A), 2 
in the 100 µg/day  cohort (Group B), 5 in the 50 µg/day cohort (Group C), 4 in the 25 
µg/day cohort (Group  D) and 4 patients were assigned to the control/placebo cohort 
(Group E) (Table 2.1). 
 
As expected, the thickness of the stratum corneum exhibited considerable inter- and intra-
variation across the tissue (Figure 2.3; Table 2.2). To control for individual variation, the 
change in thickness was calculated for each patient (-keratin thickness), by determining 
the individual baseline (pre-treatment thickness) and comparing it to post treatment 
thickness (Figure 2.4a). At the conclusion of the study, patients in group A (500 μg 
estriol/day) showed the strongest response to treatment, with a 65% average increase 
above baseline (p<0.5) (Figure 2.4b).  
 
For each patient, the number of Langerhans cells were evaluated in 72 microscopic fields 
at 10X magnification, and the final counts expressed as density of cells per mm2 of inner 
foreskin epithelium (Figure 2.5a; Table 2.3). Six of the twenty patients (one from group A, 
B, C, E and two from group D) were excluded from the density analyses due to the 
presence of an insufficient number of Langerhans cells. The results of the Welch’s t-test 
indicated that (of the remaining samples) there was no statistically significant difference 
in the number of Langerhans cells among individuals either pre- or post-treatment. 
Furthermore, there was no statistically significant change in Langerhans cell depth among 
individual pre- and post-treatments (Figure 2.5b, Table 2.3).  
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Figure 2.3 Intra- and intervariation in stratum corneum (keratin) thickness of the inner 
foreskin. Boxplot of keratin thickness differences before (striped) and after treatment 
(black) for each patient and among treatment groups. The black line in the middle of the 
boxes represents the median. The bottom and top of the boxes are the lower and upper 
quartiles, respectively. The whiskers represent the lower and upper quartile ranges, 
circles represent the outliers, and stars are extreme outliers. 
  
A B C D E 
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Table 2.2 Stratum corneum thickness of each patient pre- (baseline) and post-treatment. 
Treatment groups are shown in Table 2.1. 
 
  
Group Patient Baseline Mean ± SD Post Mean ± SD 
A CG15G 11.58 ± 3.23 14.15 ± 4.44 
A RK21G 82.37 ± 44.40 187.64 ± 115.46 
A GB24G 59.04 ± 20.64 176.34  ± 44.32 
A CC06 30.89 ± 7.17 50.60 ± 18.31   
A BG08 13.04 ± 2.83 13.48 ± 3.95 
B YW05G 22.33 ± 5.23 21.41 ± 9.46 
B TF25G 17.58 ± 4.09 16.08 ± 7.90 
C JS03G 51.43 ± 23.03 42.14 ± 21.13 
C AR06G 79.45 ± 46.83 44.88 ± 22.79 
C ML12G 79.79 ± 19.51 74.46 ± 39.61 
C TH18G 21.19 ± 4.21 15.96 ± 7.15 
C FG22G 16.14 ± 6.02 18.74 ± 8.98 
D EP08G 32.48 ± 7.13 52.72 ± 24.62 
D SD07G 22.54 ± 5.89 33.16 ± 10.45 
D DL11G 34.79 ± 20.52 32.49 ± 20.65 
D RK20G 16.22 ± 4.79 19.94 ± 10.94 
E PK02G 43.44 ±  8.02 53.44 ±  30.00 
E RM09G 37.42 ± 14.51 26.11 ±  11.20 
E JL19G 76.31 ±  34.11 138.94 ±   52.38 
E JS23G 15.00 ±  5.43 14.52 ±  4.49 
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Figure 2.4 Stratum corneum (keratin) thickness pre- and post-treatment.  
A.) Each colored line represents the change in stratum corenum thickness for an 
individual patient.  
B.) Percent change in stratum corneum thickness across groups. Error bars represent 
standard deviation of the mean. Kruskal-Wallis test was used to determine significance. 
p<0.05 
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Figure 2.5 Langerhans cell distribution pre- and post-treatment. 
A.) Comparison of average Langerhans cell density pre- and post-treatment per group. 
Error bars represent standard error. Mann-Whitney test was used to determine 
significance. 
B.) Comparison of Langerhans cell depth pre- and post-treatment. Error bears represent 
standard error. Mann-Whitney test was used to determine significance. 
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Table 2.3 Langerhans cell (LC) density and depth in human inner foreskin. 
 
N/A: No data available; †Insufficient data, ‡p value cannot be calculated 
SD, Standard Deviation 
*p<0.5,  ***p<0.0001 
aPre-treatment keratin thickness; bPost-treatment keratin thickness 
 
  
         LC NUMBER     LC DISTANCE   
    Baselinea Postb   Baselinea Postb Baseline:Post 
Group Patient Mean 
(cells/mm2)  
Mean 
(cells/mm2) 
  Mean ± SD Mean ± SD p-value 
A CG15G 1.0 1.6   0.19 ±  0.02 0.29 ±  0.13 0.2593 
A RK21G 2.0 1.4   0.12 ± 0.03 0.14 ± 0.06 0.2755 
A GB24G 0.0 1.8   †N/A †0.62 ‡N/A 
A CC06 2.1 2.1   0.34 ± 0.14 0.48 ± 0.17  ***< 0.0001 
A BG08 3.0 2.0   0.25 ± 0.08 0.19 ± 0.09 ***0.00070 
B YW05G 1.0 1.8   0.12 ± 0.04 0.18 ± 0.11 0.1764 
B TF25G 0.0 2.1   †N/A †0.24 ‡N/A 
C JS03G 1.0 1.9   0.26 ± 0.02 0.29 ± 0.14 0.9528 
C AR06G 1.1 2.0   0.24 ± 0.13 0.24 ± 0.14 0.8812 
C ML12G 0.0 1.3   †N/A †0.2 ‡N/A 
C TH18G 3.0 1.7   0.30 ± 0.01 0.21 ± 0.11 *0.0472 
C FG22G 2.0 1.8   0.17 ± 0.09 0.20 ± 0.09 0.5037 
D EP08G 1.0 1.6   †0.08 †0.17 ‡N/A 
D SD07G 1.0 1.8   †0.21 †0.26 ‡N/A 
D DL11G 1.4 1.5   0.16 ± 0.06 0.18 ± 0.08 0.8007 
D RK20G 2.5 1.2   0.17 ± 0.09 0.25 ± 0.14 0.2386 
E PK02G 1.7 2.1   0.22 ± 0.07 0.25 ± 0.12 0.711 
E RM09G 1.0 1.4   †0.19 †0.22 ‡N/A 
E JL19G 1.6 1.9   0.24 ± 0.10 0.33 ± 0.15 0.1374 
E JS23G 1.5 1.5   0.26 ± 0.04 0.25 ± 0.02 0.7621 
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2.4 Discussion 
A highly keratinized stratum corneum of the penis shaft, in addition to the removal of the 
foreskin pocket, appear to be the major contributing factors aiding in the protection of 
circumcised men against epithelial transmission of HIV. We present here the first study 
directly assessing the in vivo response of the inner foreskin of uncircumcised men to 
topical estriol, and its subsequent effect on increased thickness of the stratum corneum. 
Since estrogens are known to affect immune cell migration and maturation, we also 
examined how treatment affected Langerhans cell number and distribution in the inner 
foreskin epithelium. Estriol was chosen for the treatment since it is the weakest occurring, 
natural form of estrogen identified in men, typically circulating in the range of 10-40pg/ml 
in blood. Estrogen has been shown to affect keratin production in the rat vaginal 
epithelium [125]. Furthermore, studies in the vaginal mucosa (an analogous mucosal 
epithelium to the foreskin) in rhesus macaques showed that estrogen can induce a 
significant keratinization response that was sufficient to prevent SIV transmission [11, 12, 
126]. If the human inner foreskin can respond in a similar way, topical estrogen treatment 
might be able to reduce the risk of HIV infection through the intact mucosa in 
uncircumcised men.  
 
We have previously reported that the human male inner foreskin contains estrogen 
receptors and responds rapidly to topical estriol application by increased desquamated 
cells [110]. These findings suggested that human inner foreskin is indeed able to respond 
to estrogen by thickening the stratum corneum. No adverse reactions to the estriol 
treatment were reported by the men. This is likely due to the low dose of estriol applied, 
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its easy metabolism, and the short overall length of the study (two weeks). Our data shows 
that patients given the highest dose of estriol exhibited an average of 80% increase in 
stratum corneum thickness over the placebo group. The mean thickness after treatment 
also appeared to decrease in some patients in the lower treatment groups, although none 
of the values were significantly different from placebo. This is most likely due to the effect 
of small sample size coupled with large amounts of individual variation [127]. In addition, 
the lower treatment groups received significantly less estriol than group A. This was 
intentional, as we were attempting to define a minimum dose and effective epithelial 
responses to estrogen have been reported at low doses in female rhesus macaques [11]. 
However, it would appear that the human male inner foreskin mucosa is much less 
responsive to estriol compared to the vaginal epithelium of female macaques and requires 
a higher dose to elicit a keratin response. In subsequent studies, we would recommend 
the use of a reduced dose, but higher than 100 µg/day of estriol.  
 
Having confirmed that our highest dose of estrogen can increase the keratin barrier of the 
inner foreskin, we next investigated if it had any negative impact on Langerhans cells. 
Langerhans cells are the primary target of HIV entering the intact mucosa. Previous 
studies have shown that estrogen may affect the differentiation of Langerhans cells in 
vivo which in turn could increase the number of HIV target cells in the treated epithelium 
[128]. Such changes could affect the safety of estrogen treatment by increasing the ability 
of HIV to infect the intact foreskin, especially if there was break in the stratum corneum. 
Previous studies suggest that estrogen, produced locally in the skin, can promote 
Langerhans cell differentiation ex vivo [128]. If this same mechanism is operating in the 
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mucosa, then the number of LCs present in the epithelium could be altered following 
treatment with estrogen. However, we found that there was no difference in the total 
number or distribution of Langerhans cells between treatment and placebo groups. The 
difference in our results could be due to the potency of the estrogen used (estriol versus 
estradiol benzoate) or the route of administration (topical versus systemic). We chose to 
use estriol instead of estradiol because it is a weaker estrogen that exhibits a rapid 
metabolic breakdown, resulting in very low serum levels which may not be enough to 
affect LC maturation. A topical route of administration allows us to focus our study on the 
local effects without the risk of triggering broader physiological responses that would be 
observed following systemic administration of estrogen. 
 
Together, these data indicate that topical estriol administration is an effective method for 
specifically eliciting increased keratinization of the inner foreskin mucosa without affecting 
the biology of the underlying immune cells. Despite our small sample size, we were able 
to see an increase in stratum corneum thickness in the inner foreskin using the highest 
dose. This result is in agreement with the effect of estrogen on other skin types. Although 
statistical significance was not achieved in the lower treatment groups compared to the 
placebo in this limited data set, if the sample size is expanded in future studies, it may 
possibly allow for a more thorough investigation of estriol’s effect on keratinization at low 
concentrations. A phase II clinical trial is warranted to further evaluate the efficacy of 
topical estriol in inducing keratinization of the inner foreskin. In addition, studies will need 
to be performed to evaluate the potential for topical estriol to protect the inner foreskin 
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against HIV transmission. If proven effective, estriol could provide a useful adjunct to 
circumcision to decrease the uncircumcised male’s risk of acquiring HIV infection. 
  
 
 
 
    
 
 
Chapter 3 
Transcriptional response of the human inner 
foreskin to topical estrogen
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3.1 Background 
Several studies have been conducted demonstrating the effects of estrogen on the 
physiology of the skin. Estrogen has the ability to affect the skin at both the cellular and 
molecular levels; it can increase cell proliferation, keratin production, and the migration 
and maturation of immune cells, all of which have implications for the susceptibility of the 
skin layer to infection. Although some of these estrogen-driven effects have been 
modeled in other areas of skin, to our knowledge, they have never been described in the 
foreskin mucosa.  
 
Estrogen’s genomic effects are largely mediated through intracellular receptors present 
in various cells in the skin, including the most abundant cells in the epidermis, the 
keratinocytes [113]. Upon ligand binding, the estrogen receptor complex translocates into 
the nucleus where it binds to specific consensus sequences (known as estrogen 
response elements; EREs), within regulatory regions of target genes [129] (Figure 1.8). 
Transcription of estrogen responsive genes can be either activated or repressed in a 
locus- and cell-specific manner in a number of ways, including activation or repression of 
the promoter, co-factor binding and occasionally modification of chromatin structure [130]. 
Although estrogen can also induce non-genomic effects on gene expression resulting in 
regulation of signal transduction pathways and ion channels, this pathway is less likely to 
affect transcriptional processes involved in keratinocyte development and function [130]. 
 
Two estrogen receptors have been isolated and characterized in humans, ER-alpha 
(ESR1) and ER-beta (ESR2). These receptors share a high degree of sequence 
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homology and can function as heterodimers. However, estrogenic ligands have 
preferential binding affinities. 17β-estradiol (E2), the most potent form of estrogen, binds 
to both receptors with similarly high affinities [131]. In contrast, estriol (E3), the weakest 
form, preferentially binds to ESR2 while estrone (E1) prefers ESR1 [131]. Preferential 
binding among the estrogens may contribute to receptor-specific expression in different 
cell types, resulting in varied biological effects [131]. ESR1 promotes cellular proliferation 
and thus is necessary for development of the reproductive tract and mammary glands 
[132]. In stark contrast, ESR2 suppresses cell proliferation [132]. In addition, it has been 
shown that ESR2 is more widely expressed in the skin than ESR1 [130, 132]. 
 
There has been a vast amount of research published describing the effects of E2 on the 
skin, particularly in postmenopausal women and in cell culture. The effects of estrogen 
on the vaginal epithelium have been widely studied in post-menopausal women as 
estrogen is critical for the maintenance of urogenital skin [133-136]. Cessation of 
menstruation in women is associated with a decrease in estrogen production 
accompanied by decreased water and collagen content as well as loss of elasticity, which 
can all lead to vaginal atrophy [136]. Women with this condition experience thinning of 
the vaginal mucosa accompanied by dryness and itching. Topical hormone replacement 
therapy can effectively alleviate most symptoms associated with declining estrogen levels 
[133, 134]. Thinning of the mucosal skin is thought to contribute to the increased risk of 
HIV infection seen in postmenopausal women [75] as it contains densely packed LCs, 
HIV target cells in the epidermis.  
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Protection of LCs from infectious agents primarily comes from the outer protective barrier, 
the stratum corneum, formed by keratin and other structural proteins in the epithelium. 
Keratins, the predominant cytoskeletal proteins in the epithelium, are differentially 
expressed by keratinocytes [137] (Figure 1.4). Basal keratinocytes in the proliferative 
state express keratins 5 and 14 [137], as well as the proliferation marker, Ki-67 [138]. As 
cells lose their ability to proliferate, they begin to undergo terminal differentiation and 
keratins 5/14 are replaced by the expression of keratins 1 and 10 [137]. Under normal 
conditions, all suprabasal keratinocytes express these keratins, however, during wound 
repair and hyperproliferative skin diseases, the cells may begin to aberrantly express 
keratins 6 and 16 [139, 140]. As cells begin to senesce, they transition from the granular 
layer to a cornified state through crosslinking of several structural proteins responsible for 
forming the stratum corneum. Filaggrin (FLG) aggregates keratin filaments, causing the 
cells to collapse and flatten [141]. S100 calcium-binding proteins, such as S100A12, helps 
to control the differentiation of epithelial cells as the epidermal structural proteins begin 
to be expressed [142].  Loricrin (LOR), the most abundant cornified envelope protein, 
along with involucrin (IVL), the small proline-rich proteins (SPRRs), and late cornified 
envelope (LCE) proteins, function exclusively in the cornified envelope and are 
responsible for the maintenance of the stratum corneum [143].  
 
Enhancing the strength of the stratum corneum may improve its ability to resist infection. 
It has been noted in the literature that the thickness of the epithelium may correlate affect 
susceptibility to infection [144]. Female rhesus macaques challenged with SIV after 
treatment with estrogen have a decreased rate of infection compared to their untreated 
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counterparts and exhibit vaginal epithelial thickening [12]. In Chapter 2, we demonstrated 
that estriol augments the thickness of the stratum corneum in the inner foreskin. We 
hypothesized that there are two ways to increase keratin production: 1.) accelerated cell 
division or 2.) an accumulation of more keratin than normal in each cell. Understanding 
estrogen’s effect on keratinocyte function and foreskin biology as a whole may shed light 
on its ability to reduce HIV transmission in uncircumcised males. 
 
Estrogen responsive genes, such as CCND1 and IGFBP4, are involved in cell cycle 
regulation, which can influence cell proliferation, differentiation, and apoptosis [145, 146]. 
Estradiol has been reported to act as a keratinocyte mitogen, stimulating proliferation and 
decreasing apoptosis in vitro [111-113]. This role suggests that exogenous estrogen 
could be advantageous in the re-epithelialization process during wound healing [92]. In 
fact, estrogen has been shown to affect wound healing by regulating genes associated 
with a variety of biological processes including epidermal function [147]. TGF-β1 is 
another key gene involved in wound healing that is essential for development and 
maintenance of steady-state Langerhans cells (LCs), the primary immune cells in the 
epidermis [148]. Estrogen has been shown to affect Langerhans cell maturation and 
antigen presenting capacity through the release of chemokines and cytokines [149]. 
However, the LC migration marker CCR7, co-stimulatory marker CD86, and maturation 
marker CD83 are not affected by its presence [150]. LC maturation and antigen 
presentation are critical for initiating a proper adaptive immune response to pathogens, 
such as HIV.   
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Productive HIV infection requires the fusion of the virus membrane to the target cell 
membrane mediated by viral envelope proteins (e.g. gp120) and target cell surface 
receptors such as CD4 and its co-chemokine receptors, CCR5 and CXCR4 (Figure 1.7). 
The CCR5 receptor facilitates the entry of macrophage-tropic HIV-1 strains (R5 viruses) 
while CXCR4 mediates entry of T-cell tropic strains (R4 viruses). Treatment of 
ovariectomized mice with estradiol increases CD4+ T-lymphocyte expression of CCR5 
[149]. The stratified epithelia of genital tissues are populated by T cells, LCs and 
macrophages, all of which express the CD4, CCR5 and CXCR receptors. In addition, the 
sub-epithelium is densely populated with dendritic cells, T cells and macrophages 
expressing CD4, CCR5 and CXCR4 receptors. Due to the expression of these known 
HIV-1 receptors, immune cells of the epithelium and sub-epithelium are highly susceptible 
to HIV-1 infection. Estrogen has been shown to elevate expression of CCR5 on CD4+ T-
cells [114] which could potentially increase T-cell susceptibility to HIV infection. How each 
of the cell types described and their HIV-1 receptor expression is affected by topical estriol 
treatment needs further investigation.  
 
Almost nothing is known of the molecular pathways that control foreskin proliferation and 
keratin deposition to protect against pathogens. There is a need to take a global look at 
estrogen’s effect on gene regulation in the foreskin to help determine efficacy of this 
treatment in reducing HIV infection in uncircumcised males. Whole transcriptome 
sequencing allows researchers to perform a comprehensive, systematic comparison of 
similarities and differences in expression of a substantial number of genes across treated 
and untreated samples. The data generated could reveal many pathways that could be 
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modified to increase resistance of the epithelium to infection. We have assessed how 
topical estriol treatment regulates keratinization and epithelial thickening by defining 
changes in the transcriptional profile of normal foreskin tissue and that of treated tissue 
after exposure to estriol, the weakest naturally occurring estrogen. We surveyed the 
transcriptome for epithelial pathways that were affected by estrogen treatment, most 
notably the terminal differentiation pathway. In our data analysis, we explored the 
expression of markers corresponding to both proliferation and differentiation processes. 
In addition, we analyzed genes involved in HIV susceptibility in the epidermis. These data 
can be correlated with the morphological and physiological changes discussed in Chapter 
2 to add a greater depth to our understanding of foreskin biology and its modulation with 
estrogen treatment. This approach may also enable us to identify other molecules that 
can potentially be used to target keratin production or regulate epithelial immunity. 
 
3.2 Methods 
Localization of Filaggrin and Involucrin in the Inner Foreskin 
Double immunofluorescence was performed to assess filaggrin and involucrin expression 
within the inner foreskin epithelium. Sections were dewaxed, rehydrated, and blocked 
with 10% BSA (Sigma Aldrich, St. Louis, MO, USA). Two primary antibodies, a rabbit 
polyclonal anti-filaggrin antibody (Abcam, Cambridge, MA, USA) and a mouse 
monoclonal anti-involucrin antibody (Abcam, Cambridge, MA, USA), were mixed in 1X 
PBS in a 1:250 and 1:100 dilution, respectively and applied to the tissue for one hour at 
room temperature. After three washes in 1X PBS, a mixture of two secondary antibodies, 
FITC-conjugated goat anti-rabbit (Abcam, Cambridge, MA, USA) and FITC-conjugated 
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chicken anti-mouse, were applied using a 1:100 dilution prepared in 1X PBS. Slides were 
washed three times with 1X PBS. To visualize the nuclei, 4',6-Diamidino-2-Phenylindole 
(Dapi, Invitrogen, Carlsbad, CA, USA) was applied to each section. Each slide was cover 
slipped using Prolong Gold antifade reagent (Invitrogen, Carlsbad, CA, USA) to preserve 
the fluorescent signal during long-term storage. Images were captured using DeltaVision 
RT Systems with SoftWorx software (Applied Precision, Issaquah, WA).   
 
Tissue Samples for RNA Seq 
Foreskin from two patients (GB and RK) treated with the highest estrogen dose (500 μg 
estriol/day) and two (PK and JS) from the placebo group were selected for whole 
transcriptome sequencing. The patients selected from the highest treatment group were 
most affected by the treatment (measured by the highest response to treatment), while 
those selected from the treatment group were the least affected by treatment. All samples 
were handled in accordance with the guidelines of the Austin Health Institutional Review 
Board (Melbourne, Australia).  
 
RNA Extraction  
Total RNA was extracted using the Qiagen RNeasy Midi Kit’s protocol for isolation of total 
RNA from heart, muscle, and skin tissue. RNA concentration and integrity was 
determined via Nanodrop 1000 spectrophotometry and gel electrophoresis, respectively. 
A DNase digestion was performed using the Ambion Turbo DNA-free Kit to ensure that 
any residual DNA was removed. Again, the RNA concentration was determined via 
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Nanodrop 1000 spectrophotometry. About 10 µg (Invitrogen RiboMinus Transcriptome 
Isolation Kit Human/Mouse) or 5 µg (Epicentre Ribo-Zero rRNA Removal Kit 
Human/Mouse/Rat) of DNased total RNA was subjected to ribosomal RNA depletion 
according to the manufacturer's protocol. A  set of external RNA standards (External RNA 
Control Consortium [ERCC] RNA Spike-In Control Mixes, Life Technologies) were mixed 
with the total RNA during the initial step of the enrichment process. A 1:10 dilution of Mix 
1 was added to the treated samples and a 1:10 dilution of Mix 2 was added to the control 
samples in the Ribominus preparation. In the Ribozero preparations, a 1:10 dilution of 
Mix 2 only was added to both the treated and control tissues. The quality and quantity of 
the purified RNA was determined using the RiboGreen RNA Quantification Reagent and 
Kit (Molecular Probes) and the Experion RNA HighSens Analysis Kit (BioRad) according 
to the manufacturer's protocol. 
 
Library Preparation  
Two whole transcriptome libraries were constructed using the SOLiD Total RNA-Seq Kit 
according to manufacturer’s instructions: one for the treated sample and the other for the 
control sample. Briefly, rRNA-depleted total RNA for all samples was fragmented using 
RNase III, ligated, and reverse transcribed into cDNA. The cDNA library was purified and 
size-selected using the Agencourt AMPure XP Reagent, then amplified by PCR using 
barcoded SOLiD 3’ primers from a SOLiD RNA Barcoding Kit which adds unique 
sequences to the PCR product to distinguish between multiple libraries being sequenced 
simultaneously. The amplified DNA was purified using the PureLink PCR Micro Kit 
(Invitrogen) and the concentration measured on the NanoDrop Spectrophotometer. The 
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Agilent DNA 1000 Kit and the 2100 Bioanalyzer were used to determine the size and 
quantity of the purified library. RNA-Seq mapping is more efficient when library inserts 
are longer than 200 bp. The protocol recommends the use of libraries with less than 50% 
of the DNA falling into the 25-200 bp range. Our libraries were within range, so we 
proceeded with the SOLiD template bead preparation.  
 
SOLiD Sequencing 
Whole transcriptome next-generation sequencing was performed at the Center for 
Applied Genetics and Technology, University of Connecticut. Briefly, the barcoded cDNA 
libraries were pooled and libraries were amplified on P1 beads by emulsion PCR, 
generating bead clones. The enriched beads were deposited on a glass slide and single-
end sequencing (up to 50 bases) was performed on the Applied Biosystems SOLiD 4 
System (Life Technologies). 
 
Mapping Reads 
 Cutadapt was used to locate and remove adaptor sequences and low quality bases (a 
quality score of less than 20). After trimming any remaining reads that were less than 
20bp long were removed. The reads were then aligned to the human genome (hg19) 
using TopHat2.   
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Expression quantification and identification of differentially expressed genes 
GFOLD was used to quantify the mapped reads and normalize read counts by calculating 
the reads per kilobase per million reads (RPKM). RPKM, an expression of the relative 
abundance of transcripts, is calculated by dividing the number of reads mapped per 
kilobase of exon model by the total number of mapped reads in the entire dataset [151]. 
Differential gene analysis was performed using GFOLD which ranks differentially 
expressed genes and is particularly useful when there is no biological replicate samples 
available. GFOLD estimates the relative change in expression levels of genes based on 
their fold change to determine which genes are differentially expressed. All genes that 
were identified as statistically significantly different by GFOLD were entered into DAVID 
to identify the enriched (overrepresented) ontological categories (GO terms) in the 
dataset and to explore any Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathways that were affected by the treatment. 
 
Validation of Select Differentially Expressed Genes 
Quantitative reverse-transcription polymerase chain reaction (RT-qPCR) was performed 
to validate genes of interest using β-actin as the housekeeping gene. In addition, we also 
sought to validate the SOLiD results of genes involved in HIV binding, Langerhans cell 
maturation and migration, as well as those related to the keratinization pathway. Briefly, 
total RNA from the treated and control samples was DNased as described above and 
reverse transcribed into cDNA using the SuperScript III First-Strand Synthesis System for 
RT-PCR (Invitrogen). Primers were designed using NCBI’s primer construction software 
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Primer-BLAST (Table 3.1). mRNA abundance was determined using iQ Sybr Green 
Master Mix (BioRad). Reactions were run in triplicates on the Bio Rad CFX96 Real Time 
PCR machine. The fold change in expression of each gene from the housekeeping gene 
was calculated using the 2-ΔΔCT method. Significance was determined using t-test. p<0.05 
was considered statistically significant. Error bars represent standard deviation (SD).  
 
3.3 Results 
Immunostaining was performed on control and treated inner foreskin tissues to determine 
if estriol treatment affects the expression of epidermal terminal differentiation markers, 
filaggrin and involucrin (Figure 3.1). In both the treated and control tissues, cytoplasmic 
staining of filaggrin was observed in the upper stratum spinosum and throughout the 
stratum granulosum as expected. Treated and untreated tissues also had similar and 
expected staining patterns using the involucrin antibody, where staining was observed in 
the upper stratum granulosum and the stratum corneum of all tissues analyzed. However, 
the epithelium as a whole appeared to be thicker after treatment due to an increase in 
keratinocyte cell volume. Immunostaining allowed us to identify the presence of these 
proteins, however, it cannot be used to accurately quantify the specific expression of the 
genes. To quantify gene expression we used a combination of next-generation whole 
transcriptome sequencing and quantitative RT-PCR. To quantify the change in 
expression level of genes from estrogen and placebo treated inner foreskin, we examined 
the transcriptome from two patients assigned to the highest estrogen treatment group and 
two patients from the placebo group. Total RNA was subjected to ribosomal RNA 
depletion and the resulting RNA pool was deep-sequenced using the Applied Biosystems  
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Figure 3.1 Co-localization of filaggrin and involucrin in human inner foreskin. 
Immunohistochemistry was employed to determine the expression pattern of epidermal 
differentiation proteins, filaggrin and involucrin, before and after treatment with estrogen.  
Despite a thicker epithelium post-treatment, the expression of the proteins do not appear 
to be altered. 
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SOLiD 4 platform. On average, 50 million or more reads were generated for each sample 
across the two runs. Reads were quality filtered by removing low quality base pairs, 
adaptors, and any reads shorter than 20bp. Reads were mapped to human rRNA using 
Bowtie2 and any aligned reads were removed (about 5%). The total remaining reads (202 
million) were mapped to the University of California Santa Cruz (UCSC) hg19 human 
reference assembly using TopHat2. A combined 129 million reads (65%) were generated 
from every library that passed the filter (PF) and were aligned to the reference genome. 
Furthermore, 33% of mapped bases corresponded to exons, 31% to introns, and 35% to 
intergenic regions.   
 
A principal components analysis (PCA) was performed using RPKM values for all four 
samples across the two runs to reduce the dimensionality of the data into a three 
dimensional space (Figure 3.2). In doing so, we were able to observe similarities in gene 
expression patterns across the groups of samples. PCA showed that the two runs for 
each sample along with two technical replicates, returned very similar expression 
patterns. The PCA analysis also showed tight clustering of the placebo-treated samples 
compared to the estrogen-treated samples, supporting differences between the 
transcriptional profiles as indicated by GFOLD. A scatterplot (Figure 3.3a) and MA plot 
(derived from the Bland–Altman plot; Figure 3.3b) confirm that the values for both groups 
are highly correlated. Our quality control measures indicate that our RNA-seq method 
provides high-quality data for further exploration of the human foreskin transcriptome and 
determination of the effects caused by estrogen exposure. 
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Figure 3.2 Principal Component Analysis (PCA) of differentially expressed genes in 
foreskin tissues with or without estrogen treatment. Trends exhibited by the expression 
profiles of treated (GB and RK) and non-treated (JS and PK) tissues. Each label 
represents a sample and the type of run. 
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Figure 3.3 Differential expression analysis of estrogen treated and control inner foreskin 
tissues.  
a.) Scatterplot of genes expressed in foreskin tissue with or without estrogen treatment. 
Each dot represents a gene that is expressed in the foreskin. Dots along the center line 
are genes that are expressed in both treated and non-treated tissues. Red dots are genes 
that are differentially expressed, genes in gray are not differentially expressed, and genes 
in black dots are non-differentiated genes whose expression values overlap.    
b.) MA plot of average gene expression level vs fold change in foreskin tissues. M, on the 
y-axis, represents the fold change in treated vs non-treated tissues. A, on the x-axis, 
represents the mean of the treated and non-treated values of a particular gene. Dot colors 
follow the description written above. This plot shows that genes with both low and high 
expression levels are differentially expressed. 
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To measure gene expression and identify the differentially expressed genes (DEGs) 
between estrogen-treated and control inner foreskin tissues, we used GFOLD [152]. The 
normalized expression level of each gene was measured as reads per kilobase of exon 
per million reads mapped (RPKM). GFOLD, a bioinformatic software package, was used 
to calculate fold change (FC) defined as the ratio of the RPKM values obtained for 
individual genes in treated versus untreated tissues followed by a log 2 transformation of 
the data. The software also determines the statistical significance of the expression 
values.  
 
To experimentally confirm the differentially expressed genes identified by RNA-seq, the 
expression levels of select genes were validated by quantitative real-time PCR (qRT-
PCR) using the same RNA samples that were prepared for the SOLiD library construction. 
We chose three candidate genes that were differentially expressed by GFOLD. Beta-actin 
was used as an endogenous control in these reactions. In RNA-Seq data, CCR5 was up-
regulated 0.5 fold; CYP1A1 was down-regulated 3 fold; and LCE3A was also up-regulated 
3 fold. In qRT-PCR data, the results were nearly 5 fold, 5 fold, and 3.4 fold, respectively. 
Although there were differences in the magnitude of expression differences detected, the 
qRT-PCR results validated a consistent pattern in differential gene expression compared 
to those observed using RNA-seq (Figure 3.4). 
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Figure 3.4 qRT-PCR validation of three differentially expressed genes from estrogen-
treated inner foreskin RNA-Seq data. Fold changes determined from the relative Ct 
values for c-c chemokine receptor type 5 (CCR5), cytochrome p450, family 1, subfamily 
A, polypeptide 1 (CYP1A1), and late cornified envelope 3A (LCE3A) were compared to 
those detected by RNA-seq. Replicates (n = 3) of each sample were run and the Ct values 
averaged. All Ct values were normalized to beta-actin.  
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We identified a total of 23,802 transcripts in the sequenced pools, of which 1.7% (398 
transcripts) were significantly differentially expressed. Of the differentially expressed 
transcripts, 66 showed a 2 fold or higher change in expression. The statistically significant 
differentially expressed genes in the estrogen treated tissues compared to the placebo 
treated controls ranged in fold expression differences from -2.45 to 3.39. Further analysis 
of these genes revealed that 230 were up-regulated while 168 were down-regulated. 
Interleukin 20 (IL20) and late cornified envelope 3a (LCE3A) were the top two most up-
regulated genes in estrogen treated inner foreskin tissue, respectively. IL20 was up-
regulated by 3 fold, while LCE3A was up-regulated by 2.5 fold. Among the top up-
regulated genes were the cytokine secretion gene S100A12 (2 fold), and the cytokines 
IL19, IL36A, IL22, all of whose expression increased 2.5 fold. There was also a 2.5 fold 
up-regulation of small proline rich protein 2c (SPRR2C) which is associated with 
keratinocyte differentiation and keratinization.  Surprisingly, filaggrin (FLG) and uroplakin 
1A (UPK1A), both involved in epithelial cell differentiation, were the top two most down-
regulated genes. They were down-regulated about 3.4 and 3 fold, respectively. 
Cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1), involved in cell 
proliferation, was down-regulated about 3 fold. A few of the significantly differentially 
expressed genes have not yet been annotated including one in the top 25 most up-
regulated genes (LOC648691; 2.5 fold) as well as one in the top 25 most down-regulated 
genes (C8orf56; 2 fold). The top 25 most up- and down-regulated genes are shown in 
Tables 3.2 and 3.3, respectively. 
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An enrichment analysis was conducted to determine which Gene Ontology (GO) terms 
were related to over-represented or under-represented genes in our annotated 
transcriptome from treatment and placebo samples. Keratinocyte Differentiation and 
Immune Response were the most over-represented biological processes up-regulated by 
estrogen treatment (Figure 3.5), while down-regulated genes were mostly involved in the 
more generic category of Developmental Processes (Figure 3.6). DAVID was also used 
to determine which KEGG pathways were enriched in up- and down-regulated gene sets. 
The pathway most enriched with up-regulated DEGs was cytokine-cytokine receptor 
interactions. The fourteen genes contributing to this pathway are listed in Table 3.4. The 
pathway most affected by down-regulated DEGs is metabolism of xenobiotics by 
cytochrome P450. The five genes contributing to this pathway are listed in Table 3.5. 
 
In addition, we examined the data for potential negative effects of the treatment such as 
increased expression of proto-oncogenes. Among the significantly differentially 
expressed genes, there were none that were expressed only in the control tissues. 
However, there were 9 genes that were turned on only in the estrogen treated tissues 
(Figure 3.7). All 9 genes are members of the g antigen 1 (GAGE) gene family, which are 
not expressed in normal tissue, except in germ cells and certain cancer cells [153].  
 
We used our transcriptome data set to examine the expression of known estrogen targets 
as well as genes involved in HIV binding, Langerhans cell maturation, and keratinization, 
all of which are critical to our assessment of treatment efficacy. 
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Figure 3.5 Top ten Gene Ontology terms for genes significantly up-regulated in estrogen 
treated human foreskin tissues. Genes were grouped according to their biological 
processes. The top ten groups were ranked based on p-value. 
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Figure 3.6 Top ten Gene Ontology terms for genes significantly down-regulated in 
estrogen treated human foreskin tissues. Genes were grouped according to their 
biological processes. The top ten groups were ranked based on p-value. 
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Figure 3.7 Significantly differentially expressed genes turned on only in estrogen treated 
tissues from the Gage family of genes. 
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Estriol must bind to an estrogen receptor to affect gene expression. In order to determine 
estriol’s ability to affect the genes regulating the process of keratinization, we sought to 
confirm the expression of estrogen receptors alpha and beta in the inner foreskin (as 
previously reported [110, 154]). In addition, we examined if transcription levels were 
affected by the treatment. No significant difference was observed in the expression of 
either receptor in the treated or placebo foreskin (Figure 3.8).  
 
Our ultimate goal is to use this treatment as an adjunct to circumcision, to aid in reducing 
HIV transmission. The major factor contributing to HIV entry into the body is its ability to 
bind to the HIV co-receptors located on the outside of target cells. We sought to examine 
any fluctuations in the expression of these genes to determine if the treatment could alter 
HIV binding and infectivity (Figure 3.9). CD4 is the main receptor needed for viral 
attachment, while CCR5 and CXCR4 are co-receptors that can be utilized by HIV to 
complete the attachment process. The sequencing data indicated no significant change 
in the expression of CD4 and CXCR4. However, CCR5 showed a small but significant 
increase after estrogen treatment (G-fold value 0.01) in the SOLiD data but not qPCR. 
 
Langerhans cells are HIV target cells present in the epithelium of the foreskin. When LCs 
uptake viral components, the cells mature and rapidly degrade the foreign material. The 
cells then migrate to the lymph nodes to present the antigen to the T-cells. To ensure that 
estrogen treatment does not affect this process, we examined the following genes 
involved in LC maturation and migration: CD207, CCR7, CD40, CD80, CD83, CD86, and  
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Figure 3.8 Expression patterns of estrogen responsive genes. We compared the 
expression data of ESR1, ESR2, and EEIG1 generated by a.) transcriptome sequencing 
and b.) qRT-PCR.  
 
 
A 
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Figure 3.9 Expression patterns of HIV-co receptors. We compared the expression data 
of CD4, CCR5 and CXCR4 generated by a.) transcriptome sequencing and b.) qRT-PCR.  
 
  
B 
A 
 78 
 
TGF-β. LC development and ability to uptake antigens is largely mediated by TGF-β and 
CD207, respectively (Figure 3.10). There was no statistical difference in the expression 
of these LC markers. CCR7, a marker of LC migration, was found to be slightly down-
regulated, although not significantly. Neither of the maturation markers, CD40 and CD83, 
showed differential gene expression.  Finally, expression of the co-stimulatory markers, 
CD80 and CD86 increased slightly (0.5 fold), however this change was not significant. In 
contrast, expression profiles generated from qPCR demonstrate significant differential 
expression of CD207, CCR7, CD83, CD40, and CD86.     
 
Next, we examined markers of keratinocyte proliferation and differentiation (Figure 3.11). 
Analysis of keratins typically expressed in skin revealed contrasting results between the 
SOLiD data and the qPCR. The basal cell keratins 5 and 14, expressed during 
proliferation of basal keratinocytes, increased slightly after estrogen exposure in our 
SOLiD samples. In contrast, they decreased slightly in the qPCR analysis. Neither of 
these differences were significant. Cellular differentiation markers, keratins 1 and 10, 
expressed in suprabasal keratinocytes were slightly down-regulated in the SOLiD data, 
but not significantly. However, in the qPCR data, their expression increased significantly. 
Keratins 6 and 16, markers of hyperproliferation, are up-regulated in suprabasal cells 
during wound healing. These genes were up-regulated after estriol treatment, however, 
significance was only observed for keratin 6a in the qPCR data.  Other genes involved in 
the proliferation and differentiation processes, Ki67, CCND1, IGFBP4 and IVL, were not 
significantly affected by the treatment (Figure 3.12) in the SOLiD data. Quantitative PCR 
data revealed a significant increase in the latter two genes. 
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Figure 3.10 Expression patterns of Langerhans cell markers by a.) transcriptome 
sequencing and b.) qRT-PCR. 
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Figure 3.11 Expression patterns of keratin genes by a.) transcriptome sequencing and 
b.) qRT-PCR. 
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Figure 3.12 Expression patterns genes involved in keratinocyte proliferation and 
differentiation by a.) transcriptome sequencing and b.) qRT-PCR. 
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3.4 Discussion 
The incidence of many sexually transmitted diseases in uncircumcised men has been 
linked to the presence of the foreskin. Transmission rates of these STIs decreases 
dramatically after removing the foreskin through circumcision. The foreskin not only 
creates a warm and moist environment, permissive to bacterial growth and virus survival, 
but also has a thin mucosal stratum corneum permitting microbes to more readily enter 
the body. This realization led to the hypothesis that increasing the protective barrier of the 
foreskin may aid in the reduction of sexually transmitted diseases in uncircumcised men 
[72].  
 
It is well known that the outermost layer of the epithelium serves as a barrier, protecting 
the inside of the body from exposure to harmful agents such as pathogens. Estrogen has 
been shown to prevent intravaginal SIV infections in macaques by increasing the 
thickness of the vaginal epithelium [11]. In chapter 2, we determined that topical estriol 
has a similar effect on the analogous inner foreskin epithelium. However, the mechanism 
by which estriol induces this effect at a molecular level was not clear. Based on our 
histological analyses, the thicker epithelium appeared to be the result of a thicker stratum 
corneum (keratin layer) and not due to a change in the number of keratinocytes populating 
the epithelium, suggesting that estriol induces increased keratin deposition during 
differentiation rather than increasing skin proliferation. To further clarify this result, here 
we performed IHC to compare protein distribution of the epidermal terminal differentiation 
markers, filaggrin and involucrin, before and after treatment with topical estriol. 
Surprisingly, we found no difference in the localization of these markers after treatment. 
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It is has been reported that estrogen increases the expression of filaggrin in fetal rat skin 
[155, 156]. These opposing results may be attributed to differences in the thickness of the 
skin type being analyzed, as the mucosal skin in humans may not mirror the expression 
patterns in the non-mucosal skin of rats. In addition, another study has reported that 
involucrin is expressed in all suprabasal layers of the epidermis after estrogen treatment 
[157], compared to its normal limitation to the stratum granulosum. This effect was 
observed in tissues sampled from human female tongues. The tongue is a very different 
epithelial structure to the foreskin mucosa, and in addition, all our samples are from men, 
making comparisons between the two studies difficult. But together, our data suggests 
that both filaggrin and involucrin show varied responses to estrogen stimulation 
depending on the tissue context.  
 
To further characterize how estriol affects the molecular response of the foreskin 
epithelium tissue as a whole, we performed transcriptome sequencing of treated and 
control inner foreskin tissues.  Here, we provide the first insight into the transcriptome of 
human inner foreskin tissue treated with estrogen using RNA-seq, a powerful high-
throughput DNA deep-sequencing technology. A search through the PubMed database 
with the combination of key words of estrogen, foreskin, and RNA-seq retrieved zero 
results as of Sept. 1, 2014. Understanding how estrogen affects the foreskin is essential 
for assessing the efficacy of the treatment and for defining how estriol activates the 
keratinization pathways. In addition, such data may help to identify potential non-
hormonal targets that could be used to increase keratinization.  
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For RNA-seq, we used the Applied Biosystems SOLiD 4 System to perform a single-end 
run of ribo-depleted total RNA extracted from our samples. We used GFOLD to determine 
the differentially expressed genes between estrogen treated tissues and controls based 
on the mean RPKM values across the two individual biological replicate samples (from 
separate patients) in each group. We obtained at least 50 million reads per sample, which 
is generally sufficient coverage for accurate transcriptome profiling of genes of interest 
[158]. PCA analysis showed that the two estrogen treated samples had some differences 
in their gene expression profiles, suggesting the presence of skewed results in our 
sequencing data. For example, one reason why we saw up-regulation in genes 
associated with inflammatory and immune response could be due to a pre-existing, but 
unreported foreskin-associated infection in one of the patients. We could examine this 
assumption by performing qRT-PCR for genes associated with inflammation or infection 
across the two samples to see if one shows higher expression. In addition, our foreskins 
were collected from men of various ages with different previous pathologies related to the 
foreskin and ethnic backgrounds. The differences observed could indicate that the two 
control samples came from men with similar backgrounds, while estrogen may have 
induced the differential expression pattern observed in the treated patients, where 
‘normal’ state may be for them to be similar. 
 
To support the reliability of our transcriptome based DEG analyses, we performed qRT-
PCR for three differentially expressed genes (CCR5, CYP1A1, and LCE3A) and 
confirmed comparable trends to those identified through the RNA-seq analyses. 
Furthermore, estrogen has been shown to increase expression of CCR5 [114] and 
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decrease expression of CYP1A1 [159] in female mice and human endometrial cells, 
respectively. We see the same trends in our data from the foreskin transcriptome. We 
also observed an increase in the expression of the cornified envelope protein LCE3A in 
line with previous studies demonstrating its up-regulation after estrogen treatment [160, 
161]. Together these data confirm the accuracy of our transcriptome analyses and that 
estrogenic effects can be readily measured in our samples. We next proceeded with 
untargeted analyses of the transcriptome. 
 
The two most highly up-regulated differentially expressed genes identified across our data 
set were interleukin 20 (IL20) and late cornified envelope protein 3A (LCE3A), both known 
to be involved in the keratinocyte proliferation and differentiation processes. IL20 plays a 
role in hyperproliferation of keratinocytes associated with inflammation in the skin [162, 
163].  Several other interleukins involved in hyperproliferation and inflammation were also 
up-regulated in our study, including IL8, IL17F, IL19, and IL36A. LCE3A is a part of a 
family of genes that encode structural proteins incorporated into the maturing envelope 
late into terminal differentiation [164]. Proteins that cross-link structural proteins to the 
cornified envelope, such as those from the small proline-rich protein (SPRR) family were 
also up-regulated in our study, suggesting that we have induced epidermal keratinocyte 
differentiation. When all DEGs are examined as a whole, the Gene Ontology (GO) 
categories Keratinocyte Differentiation, Inflammatory Response, and Immune Response 
were overrepresented in the estrogen treated tissues. This is in alignment with estriol’s 
demonstrated ability to induce differentiation and accelerate wound healing. In addition, 
the cytokine-cytokine receptor interaction pathway was most up-regulated in the presence 
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of estriol. Cytokines are released in response to a stimulus to regulate cells involved in 
innate and adaptive inflammatory host defenses, cell growth, differentiation, as well as 
development and repair process. Keratinocytes are the major source of cytokine 
receptors although they are present on all cell types in the epidermis. 
 
The two most down-regulated differentially expressed genes across the data set were 
filaggrin (FLG) and uroplakin 1A (UPK1A), both key players in keratinocyte terminal 
differentiation. FLG is responsible for bundling the keratin filaments in keratinocytes to 
form the flattened cells comprising the stratum corneum [30, 165]. Decreased filaggrin 
expression, with normal expression of other epidermal differentiation markers has been 
reported in the literature, although this was observed in association with human skin 
diseases such as ichthyosis vulgaris and atopic dermatitis [166, 167]. In these conditions, 
a decrease in mRNA expression was observed, leading to decreased protein synthesis. 
Upon further investigation, local inflammatory responses marked by an increase in 
cytokines was determined to be responsible for the abnormal expression [166, 167]. As 
mentioned above, we also observed a marked increase cytokine expression and the 
subsequent decrease in FLG expression. However, our immunohistochemistry data 
combined with normal or increased expression of other structural genes, indicates that 
decreased expression of FLG does not cause disruption of the stratum corneum in the 
foreskin as it does in non-mucosal skin. This is supported by other studies using topical 
estrogen applications on the inner foreskin and vaginal epithelium, which did not report 
abnormalities in the integrity of the epithelium following treatment [99, 105, 109, 161]. 
UPK1A is a member of a family of urothelial membrane proteins present in the urinary 
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tract that are involved in the regulation of cell development, differentiation, and 
proliferation [168, 169]. Decreased UPK1A expression is associated with an increase in 
cell growth and differentiation. The expression of UPK1A in the foreskin has not been 
described to date, thus the novel role of uroplakin in this tissue needs to be explored. 
Another key keratinocyte differentiation gene that is found in the stratum corneum, loricrin 
(LOR), was also significantly down-regulated [170]. Although, LOR is a major constituent 
of the stratum corneum, aberrant expression does not affect formation of the stratum 
corneum [171]. Furthermore, in its absence other key proteins important in constructing 
the stratum corneum, such as the SPRRs, are up-regulated to compensate for the loss 
[172]. Our data supports these findings as we also observed an up-regulation of SPRRs.  
 
The GO category Organism Development Processes was most underrepresented in the 
estrogen treated tissues, suggesting that estriol down-regulates the transcription of genes 
involved in metabolic processes and development of the skin. Terminal differentiation of 
epidermal keratinocytes requires many posttranscriptional regulatory mechanisms [173]. 
Interestingly, many microRNAs (miRNAs), which can modulate the availability of RNA, 
were expressed in our data set. Two miRNAs, mir4709 and mir650, were found to be 
significantly up-regulated by estrogen treatment. MiRBase reports a number of predicted 
targets for both miRNAs, and while there are no validated targets for mir4709, mir650 has 
been shown to target two genes involved in cell proliferation: inhibitor of growth protein 4 
(ING4) and N-Myc downstream-regulated gene 2 (NDRG2) [174, 175]. Mir936 and 
mirlet7c were significantly down-regulated after treatment. Mir936 has only predicted 
targets, while mirlet7c has over 195 validated targets including genes involved in cell 
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cycle regulation like cyclin-dependent kinase 6 (CDK6) and high-mobility group AT-hook 
2 (HMGA2) [176].  Although the role of these miRNAs have not been studied in the 
foreskin, they may have played a role in the differential expression observed in this study. 
MicroRNA sequencing would provide a more thorough analysis to infer their role and the 
role of other miRNAs in is this tissue. Interestingly, xenobiotic metabolism was the most 
down-regulated pathway in estrogen treated tissue. Drug metabolism can be affected by 
a number of physiological factors including the age of the patient and individual inherited 
variations in drug metabolic pathways. Interestingly, CYP1A1, an enzyme responsible for 
metabolizing estrogen was most affected by the treatment. This may indicate that the 
estrogen degradation is delayed with this treatment. Excess estrogen can have a negative 
impact on some tissues in the body, therefore this discovery warrants further exploration.   
 
Modification of transcriptional regulators may be responsible for the aberrant expression 
of the GAGE genes in the estrogen treated tissue. Their function is not understood, but 
at least one gene in the family has been reported to have anti-apoptotic properties [153]. 
In addition, they may control cellular proliferation, differentiation and survival of human 
germ line cells [177]. These tumor antigens are normally only expressed by male germ 
cells and by some types of cancers [178]. In other tissue types, their closely related 
counterparts, MAGE genes, are silenced by DNA hypermethylation [179]. It has been 
widely reported in the literature that estrogen plays a role in chromatin modifications [180, 
181]. It is important to point out that GAGE genes do not cause cancer, rather the 
demethylation of proto-oncogenes. The overexpression of GAGE genes in our tissue 
samples following treatment suggests that estriol or miRNAs could be involved in 
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demethylation of these genes. Of note, we did not observe altered expression in any 
known proto-oncogenes in our data set. Hence, the nature of GAGE gene expression in 
the foreskin will need to be explored further. 
 
The predominant way that the effects of estrogens are mediated in the cell is by direct 
binding to the estrogen receptors α and β, which homo- or heterodimerize and translocate 
to the nucleus to interact with estrogen response elements. This stimulates the 
transcription of target genes, including those important for the development and 
maintenance of the some target tissues as well as cellular proliferation and differentiation. 
Although ER expression has been observed in the foreskin [154], there are no studies to 
my knowledge that have shown whether their expression is regulated by estriol. In this 
study, we report that the there was no statistically significant difference in ER mRNA 
levels between the estriol treated foreskin tissues and the control tissues. Some of the 
differential expression seen in our study may be caused by non-genomic effects of 
estrogen independent of its receptor. We can perform ChIP seq to study gene expression 
that could be caused by other transcription factors interacting with the DNA. 
 
The increased thickness of foreskin after estrogen treatment may serve to enhance 
protection of the HIV target cells present in the epithelium. Langerhans cell are the 
primary HIV target cells present in the skin, as they express CD4, CCR5, and CXCR4. 
The maintenance of CD4 and CXCR4 expression suggests that these receptors are not 
affected by estriol. However, we did observe a small but significant increase in CCR5 
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expression, warranting a closer look at why this is occurring. Our findings from Chapter 2 
suggests that the increased expression is not due the presence of more Langerhans cells 
(LCs), the primary HIV target cells in skin. Mature LCs emigrate from the epidermis to the 
draining lymph nodes where they present antigens to T-cells which also express CCR5. 
It has been shown that CCR5 expression on T-cells increases after exposure to estrogen 
[182]. This up-regulation could mean an increased risk of HIV transmission should the 
virus be allowed contact with the cells, however the likelihood of this happening is 
diminished because of our enhanced barrier. Furthermore, an absence of statistically 
significant differential expression in genes involved in migration and maturation suggests 
that estriol treatment does not affect LC function nor distribution. A more likely 
explanation, consistent with the data reported thus far, is that CCR5 is acting as a 
canonical chemokine receptor to control the inflammatory response either initiated by the 
treatment or by an existing infection [183]. 
 
We showed in Chapter 2 that estrogen increases the thickness of the stratum corneum 
of the inner foreskin. Thickening of the stratum corneum could result from increased 
proliferation of the keratinocytes (more cells increases amount of keratin fibers packed 
into the stratum corneum) or increased keratinization of the cells during differentiation 
(more keratin per cell). Keratin genes are markers of proliferation and differentiation in 
the epithelium as they are specifically expressed in different skin layers.  We did not find 
any significant difference in the expression of any of the keratin genes or other genes 
involved in the development of keratinocytes in our SOLiD data. However, the qPCR data 
revealed a significant up-regulation in the expression of keratins 1, 10, and 6a as well as 
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IGFBP4 and IVL. This discrepancy may be due variability in the number of transcripts 
generated by each preparation procedure. Quantitative PCR may be more adept at 
capturing higher transcript numbers, as it amplifies a specific gene. As reported above, 
we also found differential expression of stratum corneum development genes, such as 
LCE3a and SPRR2C. 
 
Taken together, our findings demonstrate that topical estrogen not only enhances the 
protective barrier of the foreskin but also elevates important defense mechanisms. Here 
we show that differential expression of genes in response to estriol elicit an initial 
inflammatory/immune response that is being regulated by expression of anti-inflammatory 
and anti-defense genes like DEFBs and LTF (data not shown). Furthermore, the key cells 
present in the skin, keratinocytes and Langerhans cells, are not significantly affected by 
this process. The results obtained thus far, which strongly support our hypothesis that 
estriol can be used as a potent stimulator of keratinization, are promising. However, 
further studies are needed to clarify the role of GAGE and CCR5 in our data set.  In 
addition, we need to repeat transcriptomics on additional samples to confirm consistent 
results.
  
 
 
 
 
 
 
Chapter 4 
Modeling the effect of estriol on keratin 
production in keratinocytes in vitro using the 
HaCaT cell line
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4.1 Background 
Keratinocytes, the most abundant cells in the epidermis, play two important roles in the  
skin: to replenish the epithelium and to form the outer protective barrier of skin [184]. 
These cells are packed with intermediate filaments called keratins that serve as a scaffold 
to the cytoskeleton [185]. All keratinocytes begin their existence in the basal cell layer of 
the epidermis where they are characterized by the expression of proliferative markers, Ki-
67, keratin 5, and keratin 14 [138]. During proliferation, the keratinocytes go through 
mitosis to produce an identical daughter cell that eventually undergoes terminal 
differentiation. When the cells exit the cell cycle and migrate into the suprabasal layer of 
the epidermis, expression of the proliferative markers decline and markers of epidermal 
differentiation increase [184]. Early epidermal differentiation is marked by expression of 
keratins 1 and 10, while filaggrin and involucrin are late markers of differentiation [138, 
186]. In late differentiation, keratinocytes begin to flatten and eventually only long fibers 
of keratin proteins remain along with junctional and structural proteins. This components 
comprise the primary constituents of the stratum corneum [138]. 
 
The stratum corneum marks the outermost layer of the epidermis where water retention 
is regulated and the body comes in contact with pathogens in the external environment 
[187]. Estrogen has been identified as a compound that can induce thickening of the 
stratum corneum [11, 12, 110, 188].  Studies in humans and monkeys have shown that a 
thicker protective barrier prevents transmission of viral particles into the epithelium and 
may also protect the underlying immune cells from contact with viruses [11, 12, 33, 110]. 
Our results reported in Chapters 2 and 3 of this thesis corroborates these studies by 
 91 
 
demonstrating that estrogen can induce keratinization of the inner foreskin mucosa 
through stimulation of epidermal differentiation. Uncircumcised males could greatly 
benefit from this treatment, as they are more likely than their circumcised counterparts to 
experience bacterial and viral infections [189].  
 
Studying keratinocyte proliferation and differentiation can be complicated by the complex 
structure of the dermis and epidermis in vivo. Cell culture experiments can be employed 
to reduce the complexity of cell interactions and the factors involved in keratinocyte 
proliferation and differentiation. Studies in cultured keratinocytes report that many factors 
promote differentiation, including vitamin D [190, 191] and calcium [186, 192] among 
others. The effect of estrogens are largely mediated through activation of the two key 
estrogen receptors (ERs), estrogen receptor alpha (ERα) and estrogen receptor beta 
(ERβ). Once activated, the receptors translocate to the nucleus where they bind to 
estrogen response elements and regulate gene transcription.  
 
Estrogen may increase keratin thickness in the skin by activating keratin production in the 
keratinocytes. Alternatively, estrogen may affect the keratinocytes in the basal layer of 
the epidermis, causing increased proliferation of the mitotic cells. In order for the 
keratinocytes to respond to topical estriol, they must express ERs. Assessing keratinocyte 
proliferation and differentiation in culture before and after treatment with estriol can reveal 
relevant information about its effect on keratinization at the cellular level. 
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The spontaneously immortalized human keratinocyte cell line, HaCaT, has been used 
extensively to study keratinocyte function [186, 193-195]. Unlike primary cells that have 
a finite life span and require supplementary growth factors to survive in vitro, HaCaT cells 
can be maintained in culture for longer periods of time and can be grown in conventional 
media. HaCaT cells were derived from histologically normal, male skin located in the 
distant periphery of a melanoma [32]. The name describes the specific culture conditions 
used to create the cell line; originating from human adult skin keratinocytes propagated 
under low Ca 2+ conditions and elevated temperature [32]. These conditions encouraged 
prolonged cell proliferation, while suppressing differentiation. After several passages, the 
cells overcame their dependency on the calcium and temperature requirements. Despite, 
their immortalized nature, the cells never became tumorigenic. In subsequent 
experiments, they were shown to be capable of differentiating [32] and forming a stratified 
epidermal monolayer in organotypic culture [195]. Although HaCaT cells are aneuploidy 
with duplicated chromosomes and a missing Y chromosome, they exhibit the same 
functionality and keratinocyte surface markers of proliferation and differentiation found in 
the upper layers of normal human skin [194]. 
 
HaCaT cells have been regarded as the ideal model system to study cell proliferation and 
differentiation in response to exogenous factors, such as calcium and vitamin D [186, 
193, 196]. Estrogen also has the ability to influence keratinocyte function in vivo, however, 
few studies have examined the ability of estradiol to alter proliferation and differentiation 
of HaCaTs [197-199]. Additionally, no studies have been performed using its weaker 
counterpart, estriol. We demonstrated in Chapters 2 and 3 that estriol can be used as a 
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potent stimulator of keratinization in vivo. Keratinocytes are the main cells in the 
epidermis, so we presume that they serve as the target cells upon which estriol exerts the 
majority of its regulatory effects. Langerhans cells, Merkel cells, and melanocytes are also 
very important cells present in the skin as they are responsible for viral detection and 
degradation, somatosensory, and pigment production, respectively [200] and they 
express estrogen receptors. Therefore, to accurately assess the effect of a drug treatment 
on specific biological processes, it is necessary to isolate the cells of interest. The aim of 
this study was to test the suitability of HaCaT cells as a model system to examine 
keratinocyte proliferation and differentiation in response to estriol. 
 
4.2 Methods 
Cell Culture Maintenance 
HaCaT cell stock cultures were maintained at 37°C, under 5% CO2 in 1X Dulbecco's 
Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F-12) (Invitrogen) and 
supplemented with 100 U/ml penicillin-100 mg/ml streptomycin , as well as 10% Fetal 
Bovine Serum (FBS) (Invitrogen). Throughout the methods, this mixture will be referred 
to as growth media (GM). 
 
Hormone Preparation 
Estriol (E3) (Cayman Chemical) and 17-β estradiol (E2) (Sigma-Aldrich) were solubilized 
in absolute ethanol to make a 1000X stock. E3 was diluted further in absolute alcohol to 
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0.1 µM and 10 µM working stock solutions and E2 was diluted to a 10 µM working stock 
solution. 
 
Cell Treatments 
HaCaT cells were trypsinized using 0.02% trypsin/EDTA and seeded in duplicate to a 
density of 0.4x105 cells per chamber in 8-well culture slides, 6.8x105 cells per well in 6-
well culture plates, or 0.7x105 cells per well in 24-well culture plates for 
immunohistochemistry, Western Blot analysis, and RT-qPCR, respectively.  All cells were 
grown in phenol red-free DMEM (Invitrogen) and supplemented with 100 U/ml penicillin-
100 mg/ml streptomycin, as well as 10% charcoal stripped FBS (Invitrogen). All cells were 
grown at 37°C in a 5% CO2 humidified incubator for 24 hours before treatment. Cells 
grown on the culture slides were treated with equivalent amounts of vehicle (100% 
ethanol), 0.1 nM E3, 10 nM E3, or 10 nM E2 for either 24 or 48 hours. Cells were stored 
at room temperature for use in immunostaining. For Western Blot and RT-qPCR 
analyses, cells were treated with vehicle (100% ethanol), 0.1 nM E3, 10 nM E3, or 10 nM 
E2 for 24, 48, or 72 hours. Following treatment, the cells for immunoblot analysis were 
lysed on ice with 8.5 M urea for 5 minutes. The lysate was collected and centrifuged at 
14,000 rpm for 10 minutes at 4°C. The supernatant containing the protein was collected 
for downstream analysis. For RT-qPCR, cells were harvested and total RNA was isolated 
using the attached cells protocol of the GenElute Mammalian Total RNA Miniprep Kit 
(Sigma-Aldrich). Briefly, the cells were incubated in the lysis solution/2-mercaptoethanol 
(2-ME) mixture for 2 minutes and the lysate was filtered to release the DNA and remove 
cellular debris. RNA was isolated and DNased using the Turbo DNA-free Kit (Ambion) to 
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remove any remaining DNA. The SuperScript III First-Strand Synthesis System for RT-
PCR was utilized to synthesize cDNA to be used in the qRT-PCR.  
 
Subcloning 
Untreated HaCaT cells were subcultured from a confluent plate containing about 8x106 
cells. Cells were collected in an RNase free tube and the RNA was extracted using the 
GenElute Mammalian Total RNA Miniprep Kit (Sigma-Aldrich). Briefly, the cells were 
incubated in the lysis solution/2-mercaptoethanol (2-ME) mixture for 2 minutes and the 
lysate was collected for downstream analyses. Total RNA was isolated and DNased using 
the Turbo DNA-free Kit (Ambion) to remove any remaining DNA and then converted to 
cDNA using the SuperScript III First-Strand Synthesis System for RT-PCR. The resulting 
cDNA was used to confirm expression of the estrogen receptors α and β in the HaCaT 
cells using β-actin as a housekeeping gene (Table 4.1). The PCR products were analyzed 
by standard gel electrophoresis, and bands corresponding to the estrogen receptor 
excised and purified using the Qiaquick Gel Extraction Kit (Qiagen). Purified PCR 
products were ligated into the pGEM-T Easy Vector System (Promega). The plasmid was 
used to transform JM109 Escherichia coli (E. coli) (Promega) competent cells and plated 
onto Luria broth (LB) agar, containing 100 μg/ml ampicillin and supplemented with 
80µg/ml X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) and 0.5mM IPTG 
(Isopropyl β-D-1-thiogalactopyranoside). The plates were incubated overnight at 37° C 
and white colonies containing the genes of interest were selected and grown overnight in 
LB containing 100 μg/ml ampicillin  in a 37° C shaking incubator. Following incubation, 
1.5 ml of the culture was used to isolate plasmid DNA using the QIAprep Spin Miniprep  
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Table 4.1 Sequences of the qRT-PCR primers used in this study. 
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Kit (Qiagen). Clones containing the appropriate inserts were sent for DNA sequencing at 
the DNA Biotechnology Facility at the University of Connecticut. 
 
Northern Blot 
Total RNA extracted from a HaCaT cell pellet was fractionated on a denaturing 1% 
agarose gel containing 37% formaldehyde at 40V for one hour. The RNA was transferred 
to a polyvinylidene difluoride (PVDF) membrane (EMD Millipore) during an overnight 
incubation. After briefly washing in 2X saline-sodium citrate (SSC) buffer, the RNA was 
cross-linked to the membrane using Stratalinker (Stratagene). A 32P-labeled probe 
complimentary to the ER-alpha sequence was generated via random priming. The 
membrane containing the immobilized RNA was hybridized with the labeled probe 
overnight at 62°C in Church’s hybridization buffer. After removing the blot from the 
hybridization solution and washing in 2X SSC/0.1% SDS, the bands were visualized using 
autoradiography. Briefly, the blot was placed in a film cassette, covered with a sheet of 
X-ray film and exposed at -80C for 7 days. Following exposure, the film was brought to 
room temperature before developing. 
 
Immunohistochemistry  
Immunofluorescence was performed on treated and untreated HaCaT cells to determine 
the localization of estrogen receptors α and β. The cells were fixed on their slides in 4% 
paraformaldehyde/1XPBS for 20 minutes, permeabilized in 0.2% Triton-X100/1X PBS for 
5 minutes, and blocked with 1% bovine serum albumin (BSA) for 1 hour.  After an 
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overnight incubation at 4OC with a 1:250 dilution of ER-α (Santa Cruz Biotechnology) or 
1:250 dilution of ER-β (Pierce Biotechnology) rabbit polyclonal antibodies in 1 X PBS, 
slides were washed with 1X PBS and incubated with a secondary FITC-conjugated goat 
anti-rabbit antibody (AbCam) in 1X PBS containing 1% BSA/2% FBS for 1 hour. A second 
wash with 1X PBS was followed by an incubation with a FITC-conjugated donkey anti-
goat antibody (AbCam) in 1X PBS containing 1% BSA/2% FBS for 1 hour to enhance the 
signal. Slides were washed with 1X PBS, then incubated with 4',6-Diamidino-2-
Phenylindole (Dapi) (Invitrogen) to counterstain the cell nuclei. The slides were mounted 
using Prolong Gold antifade reagent (Invitrogen) to preserve the fluorescent signal during 
long-term storage. Control sections were processed using the same protocol with the 
exclusion of the primary antibody. Images were captured using DeltaVision RT Systems 
with SoftWorx software (Applied Precision).   
 
Quantitative Real Time-Polymerase Chain Reaction 
Real-time reverse-transcription polymerase chain reaction (RT-qPCR) was performed to 
evaluate the expression of estrogen receptors (ESR1 and ESR2), epidermal keratins (5, 
14, 1, 10, 6, and 16), terminal differentiation genes (involucrin and filaggrin) and 
proliferation gene Ki-67 in treated HaCaT cells. Beta-actin was employed as the 
housekeeping gene. Primers were designed using NCBI’s primer construction software 
Primer-BLAST (Table 4.1). The mRNA was quantified using iQ Sybr Green Master Mix 
(BioRad) which contains Taq DNA polymerase, dNTPs, and MgCl2. Reactions were run 
in triplicates on the Bio Rad CFX96 Real Time PCR machine. Relative expression to a 
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housekeeping gene was calculated using the equation 2-ΔΔCT where ΔΔCT=ΔCT treated-
ΔCT untreated, where ΔCT=Avg CT of gene of interest-Avg CT of β-actin. 
 
Cell Proliferation Assay 
To evaluate the effect of estriol on proliferation of HaCaT cells, the MTS colorimetric 
assay was performed as described using the CellTiter 96 Aqueous Non-Radioactive Cell 
Proliferation Assay (Promega). This test is based on the reduction of the tetrazolium 
compound, MTS (tetrazolium, inner salt), into an aqueous, soluble formazan, which can 
only be performed by living cells. Briefly, cells were incubated at an initial density of 2.5 x 
104 cells per well in 96-well plates.  One day later, the medium was replaced by fresh GM 
and cells were treated with vehicle, 0.1 nM estriol or 10 nM estriol for 24, 48, or 72 hours.  
Following treatment, cells were incubated for 3 hours at 37° C in a humidified 5% CO2 
chamber in the presence of MTS (20 μl/100 μl of medium). The quantity of formazan 
product formed (directly proportional to number of living cells) was measured at 490nm 
absorbance. 
 
Western Blots 
Protein concentrations of treated cells were determined using the Quant-iT Protein Assay 
Kit (Invitrogen) and equal amounts of protein (10 μg lysate) mixed with 2X sodium dodecyl 
sulfate (SDS) buffer was loaded onto a polyacrylamide gel for each sample. The proteins 
were blotted onto polyvinylidene difluoride membranes (PVDF) (EMD Millipore) and 
blocked with 5% non-fate dry milk for 1 hour. The membranes were incubated overnight 
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at 4°C with monoclonal anti-epithelial keratin-AE1/AE3 mixture primary antibody (1:1000) 
(MP Biomedicals) in 1X PBS. After washing with 1X PBS, the blots were incubated with 
stabilized, peroxidase conjugated goat anti-mouse IgG antibody (1:10,000) (BioRad) in 
5% non-fat dry milk for 1 hour at room temperature. Bands were detected using the 
Western Lightning-Plus Enhanced Chemiluminescence (ECL) substrate system (Perkin 
Elmer Life and Analytical Sciences) under UV. 
 
Statistical Analysis 
The data was analyzed using InStat Version 3 (GraphPad) and One-way Analysis of 
Variance (ANOVA) was used to compare results across treatment groups, followed by 
Bonferroni Multiple Comparisons Test post analyses to determine which group means 
differed from one another. A p-value of less than 0.05 was considered statistically 
significant. Error bars represent 1 standard deviation (SD) of the mean. 
 
4.3 Results 
HaCaT cells express estrogen receptors alpha and beta 
In order to determine if estrogen receptor alpha (ESR1) and estrogen receptor beta 
(ESR2) are present in HaCaT cells, untreated cells were subcultured after reaching 
confluence. Total RNA was extracted from cell pellets and converted to cDNA, followed 
by PCR. Clones were generated, sequenced, and data obtained from the inserts were 
entered into BLAST (Basic Local Alignment Search Tool) to compare the sequence 
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generated to the known sequences for ESR1 and ESR2 genes in the human genome. 
The sequence generated for ESR2 matched the known sequence but not for ESR1 
(Figure 4.1). Northern blot analysis showed that ESR1 is also expressed in HaCaT cells 
(Figure 4.2). Immunohistochemistry analysis of untreated cells confirmed protein 
localization of both ESR1 and ESR2 (Figure 4.3). Moreover, ESR1 exhibited cytoplasmic 
staining (Panel A) while ESR2 showed punctate staining in the nucleus (Panel B).  
 
Estrogen activates and up-regulates the estrogen receptors alpha and beta in 
keratinocyte culture  
The expression of the estrogen receptor alpha and estrogen receptor beta genes in 
response to estrogen treatment were studied in HaCaT cells using immunostaining and 
RT-qPCR. Cytoplasmic staining of ESR1 and ESR2 was observed in the absence of 
estrogen at 24 and 48 hours (Figures 4.4 and 4.5; Panels A and E). Low dose estriol (0.1 
nM E3) activates both ESR1 and ESR2 within 48 hours as shown by the predominant 
nuclear localization in Panel F. Higher doses of estrogen, 10nM E3 and 10 nM 17β-
estradiol (E2) causes complete translocation of ESR1 and ESR2 into the nucleus with 24 
hours (Panels D). 
 
 After treatment, ESR1 mRNA levels were significantly up-regulated across all treatments 
and time points, with a marked increase in cells treated with a high concentration of E3 
or the main endogenous estrogen, E2 (Figure 4.6). After 24 hours of treatment with 0.1nM 
E3, 10nM E3, or 10 nM E2, ESR1 expression increased 1.7 fold (p<0.05), 4.7 fold  
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Figure 4.1 ESR 2 expression in untreated HaCaT cells. 
 
 
  
 103 
 
Figure 4.2 Northern blot demonstrates ESR1 expression in untreated HaCaT cells. 
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Figure 4.3 Untreated HaCaT cells express ESR1 and ESR2.   
A.)  Cytoplasmic staining of ESR1 in untreated HaCat cells cultured for 24 hours. 
B.) Punctate nuclear staining of ESR2 in untreated HaCat cells cultured for 24 hours. 
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Figure 4.4 ESR1 expression in HaCaT cells treated with estriol at 24 and 48 hours. In the 
absence of estrogen, ESR1 localizes in the cytoplasm. High levels of estrogen can induce 
translocation of ESR1 to the nucleus in as little as 24 hours. All forms of estrogen have 
this effect by day 2. 
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Figure 4.5 ESR2 expression in HaCaT cells treated with estriol at 24 and 48 hours. ESR1 
responds to both low and high levels of estrogen treatment in 24 hours. This expression 
is maintained at 48 hours. 
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Figure 4.6 ESR1 mRNA expression in treated HaCaT cells. 
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(p<0.001), and 8 fold (p<0.001), respectively. The same treatments after 48 hours, 
induced a 1.8 fold (p<0.01), 3.7 fold (p<0.001), and 8.1 fold (p<0.001) increase in 
expression. After 72 hours, ESR1 expression continued to increase above the control at 
2.6 fold (p<0.001), 3 fold (p<0.001), and 4.8 fold (p<0.001). 
 
A similar increase in ESR2 expression was observed, however, only the higher 
concentrations of E3 and E2 were able to stimulate a significant up-regulation (Figure 
4.7). In 10 nM E3 treated cells, ESR2 expression increased 2.1 fold (p<0.05), 3.3 fold 
(p<0.01), and 2.8 fold (p<0.001) after 24, 48, and 72 hours, respectively. E2 treated cells 
showed a 2. 7 fold, 3.4 fold, and 3.1 fold increase across the same time points.  
 
Estrogen promotes terminal differentiation but not proliferation of keratinocytes 
MTS is a tetrazolium used to monitor cell viability in culture. Measurement of MTS 
reduction by cells revealed that estriol does not stimulate proliferation of HaCaT cells, 
regardless of dosage (Figure 4.8). Although, there was a trending decline in the number 
of cells present, no statistical significance was reached when compared across 
treatments. Furthermore, the more potent E2 treatment also failed to induce significant 
proliferation. To further assess the effect of estrogen on keratinocyte proliferation, we 
performed a Western Blot to analyze the production of basal keratins 5 and 15, markers 
of proliferating keratinocytes in skin as well as keratins 6 and 16, markers of 
hyperproliferation in culture. A pan keratin antibody was used for immunoblotting that 
detects every known keratin. Specific keratins can normally be identified by their  
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Figure 4.7 ESR2 mRNA expression in treated HaCaT cells. 
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Figure 4.8 Cell Proliferation Assay using treated HaCaT cells. 
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molecular weight, however, we were unable to resolve the bands to identify keratins of 
interest (Figure 4.9). We did observe keratins being produced at earlier time points than 
normal when treated with estrogen. This expression continued to increase over longer 
treatment times. Quantitative mRNA analysis of the keratins revealed a significant 
decrease (nearly 1 fold; p<0.01)) in keratin 5 production after treating with high dose 
estrogens for 48 hours, however, this decrease was not evident at 24 or 72 hours (Figure 
4.10). Keratin 14 showed a three quarter fold decrease (10 nME3: p<0.05; 10 nM E2: 
p<0.01) in the presence of high levels of estrogen 24 hours after treatment (Figure 4.11). 
The decline observed at 48 and 72 hours failed to reach significance. Both keratins 6 and 
16 also decreased significantly after 24 hours of treatment in all treatment groups (UT v 
0.1 E3: p<0.05; UT v 10nM E3: p<0.01; UT v10 nM E2: p<0.001) (Figures 4.12 and 4.13). 
Keratin 6 expression did not change significantly at later time points. Keratin 16 
expression at later time points only changed significantly after E2 treatment at 48 hours., 
where there was a nearly one fold (p<0.05) decline in mRNA abundance. Quantitative 
mRNA analysis of the standard marker of proliferation, Ki-67, showed that cell 
proliferation did not change after exposure to estrogen (Figure 4.14).  
 
To determine estrogen’s effect on terminal differentiation of keratinocytes in culture, 
production of suprabasal keratins 1 and 10 were examined in HaCaTs using Western Blot 
analysis, followed by RT‐qPCR. Because keratins in aging cells are critical for proper 
stratum corneum formation, we also investigated whether mRNA expression of filaggrin 
(FLG) and involucrin (IVL), two epidermal differentiation markers, is altered in estrogen-
treated HaCaT cells. As stated above, we were unable to resolve bands of the  
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Figure 4.9 Western Blot analysis of keratin proteins. 
 
 
  
 113 
 
Figure 4.10 Keratin 5 mRNA expression in treated HaCaT cells. 
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Figure 4.11 Keratin 14 mRNA expression in treated HaCaT cells. 
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Figure 4.12 Keratin 6 mRNA expression in treated HaCaT cells. 
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Figure 4.13 Keratin 16 mRNA expression in treated HaCaT cells. 
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Figure 4.14 Ki67 mRNA expression in treated HaCaT cells. 
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immunoblot, but we did notice a trend for increased keratin production in the presence of 
estrogen. There was a near 2 fold increase in keratin 1 mRNA production after the 24 
hour treatment with E2 (p<0.05) (Figure 4.15) and a 1.5 fold increase in keratin 10 treated 
with high doses of estrogen E3 and E2 (p<0.05) (Figure 4.16). RT‐PCR results 
demonstrated a rapid up-regulation of both filaggrin and involucrin. Filaggrin exhibited a 
small increase in all treatment groups following 24 and 48 hours of treatment with all 3 
estrogen doses (Figure 4.17). Involucrin showed a significant increase only with 10nm E2 
treatment after 24 hours (p<0.05), but maintained a significant increase in all treatments 
at the longer time points (Figure 4.18).  
 
4.4 Discussion 
The aim of these studies was to assess the viability of using an in vitro model system to 
further define the effects of estriol on the production of keratin.  The skin is a complex 
tissue comprised of multiple cell types that express ERs, making them potentially 
responsive to estrogen. Keratinocytes, the primary producers of the stratum corneum, are 
known to be estrogen responsive and greatly outnumber all other cells in the skin. We 
reasoned that estrogen exerts the majority of the actions we have observed thus far on 
this cell type. Chapter 3 of this thesis suggests that estriol stimulates differentiation of 
keratinocytes, leading to a thicker stratum corneum, which could protect against viral and 
bacterial infections. However, the tissues used in Chapter 3 contained a diverse array of 
cell types within the skin from both the dermis and epidermis, making it difficult to 
determine the precise effect on our primary target cell, the keratinocytes. Therefore, to 
directly assess estriol’s effect on keratinocyte development, we used the spontaneously 
 119 
 
Figure 4.15 Keratin 1 mRNA expression in treated HaCaT cells. 
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Figure 4.16 Keratin 10 mRNA expression in treated HaCaT cells. 
  
 121 
 
Figure 4.17 Filaggrin mRNA expression in treated HaCaT cells. 
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Figure 4.18 Involucrin mRNA expression in treated HaCaT cells. 
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immortalized and very well characterized HaCaT cell line. We examined the expression 
of cell proliferation and differentiation genes in the presence of the estriol. Here I describe 
the effect of low dose estriol (0.1 nM E3), high dose estriol (10 nM E3), and high dose 
17β-estradiol (10 nM E2) on cell growth and differentiation in this cell line and discuss 
how it relates to the treatment of inner foreskin in vivo and the overall suitability of HaCaT 
to assess estrogen effects on the mucosa. The results of these studies could be expanded 
to in vitro foreskin organotypic culture to test estriol’s ability to reduce HIV transmission 
in a controlled manner. Our ultimate goal is to translate this new knowledge into a novel 
clinical use of estriol for uncircumcised men.  
 
HaCaTs are similar to normal keratinocytes, however, as with most immortalized cell 
lines, it exhibits chromosomal abnormalities resulting in aneuploidy and duplications of 
certain chromosomal regions [32]. Despite being immortalized, the HaCaT cell line is 
regarded as a suitable and stable model for studying keratinocyte physiology in vitro as it 
retains the capacity to undergo full epidermal differentiation while remaining non-
tumorigenic. In addition, the presence of proliferation marker Ki-67, proliferation specific 
keratins (K5 and K14), differentiation specific keratins (K1 and K10) and epidermal 
markers of differentiation (filaggrin and involucrin) have been confirmed in this cell line 
[23, 201, 202]. 
 
We verified through immunohistochemistry that HaCaT cells express the estrogen 
receptors alpha (ESR1) and beta (ESR2) supporting previous work from Alexaki et al 
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[203] using immunoblotting. In the absence of exogenous estrogen, ESR1 appeared to 
localize to the cytoplasm, while ESR2 showed punctate staining in the nucleus. Nuclear 
staining of ESR2 suggests activation of the receptor by an endogenous factor in the 
media. Indeed, it is known that phenol red, a pH indicator in culture media, is a weak 
estrogen receptor agonist and normal serum typically contains estrogens [204]. Therefore 
all cell work performed beyond this point was carried out in phenol red-free, charcoal-
stripped serum media to abolish the effect of any endogenous hormones present in the 
samples.  
 
We have demonstrated that both receptors respond to weak (E3) and potent (E2) 
estrogens. ESR1 and ESR2 mRNA was detected in the keratinocyte cultures with a 
higher mean level of ESR1 expression than ESR2. In addition, ESR1 expression was up-
regulated as early as 24 hours after exposure to the lowest dose estrogen treatment 
(0.1nM E3), while ESR2 showed a significant response only in the presence of higher 
treatments (10nM E3 and 10nM E2) during the same time frame. This suggests that ESR1 
co-expressed with ESR2 may play a dominant role in early gene regulation in HaCaT 
cells. These results are in alignment with, Verdier-Sevrain et al. who also observed 
increased ESR1 and ESR2 mRNA levels in human neonatal keratinocytes treated with 
E2 [113]. Taken together, these findings suggest that treatment of keratinocytes with 
estriol causes transient up-regulation in the expression of the estrogen receptors.  
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We were primarily interested in determining the effect of estriol downstream of ER 
activation, regulating genes driving proliferation and differentiation in keratinocytes. 
Western blot analysis revealed an acceleration in overall keratin production in the HaCaT 
cells in response to estrogen treatment, supporting the results of chapter 2 and 3 and 
previous papers on wound healing and alterations of the vaginal epithelium. Our cell 
proliferation data did not show a significant change in the number of keratinocytes under 
different estrogen exposures during the time frame examined. This supports our in vivo 
data from Chapter 2 and 3 which also showed no increase in skin proliferation rates. 
However, these results are in conflict to what has been previously reported in the skin. 
One study using epidermal keratinocytes from newborn foreskin reported an increase in 
proliferation following 0.1 nM E2 treatment [113, 205]. A second study using normal 
human epidermal keratinocytes from adult female breast skin showed increased 
proliferation at lower concentrations of E2 (0.01 nM and 0.1 nM) but this switched to a 
decrease in proliferation in the presence of higher concentrations (1 nM, 10 nM, and 100 
nM) [205]. Further investigation is needed to uncover the cause of the differences 
observed between the studies, which could be due to a number of factors including in 
vivo versus in vitro, donor age (newborn versus adult), gender disparities, or anatomical 
site (back skin vs. breast tissue). It is also important to note that the previous studies were 
carried out in primary cell culture in which keratinocytes rapidly die following differentiation 
[193]. A decline or maintenance in proliferating keratinocytes could indicate that most of 
the HaCaT cells have converted into a differentiated state following estrogen treatment. 
Our cell cultures did not reach confluency at the time points we sampled. To confirm that 
HaCaT cells were differentiating, we showed by RT-PCR that the late terminal 
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differentiation markers, filaggrin and involucrin, are up-regulated at 24 hours and 48 hours 
post-treatment regardless of dosage. Up-regulation of these markers is consistent with 
previous reports in the literature during differentiation of this cell line [193, 194, 206]. 
However, the HaCaT data is in contrast to our in vivo sequencing data from Chapter 3 
that showed filaggrin expression was reduced in the presence of estriol, while involucrin 
expression was unchanged. The complexity of the skin in vivo versus the simplicity of the 
culture system in vitro could play a large role in this difference. Estriol may exhibit different 
effects on cellular pathways depending upon the environmental context of the 
keratinocyte. The mucosa of the inner foreskin is a highly specialized epithelium that is 
likely maintained by multiple intercellular signaling pathways which are lost in the HaCaT 
monoculture. Expression of other terminal differentiation markers could provide better 
insight into this phenomenon and the suitability of HaCaT to model for mucosal tissues.  
 
Taken together, our results indicate that estriol accelerates keratin production in HaCaT 
cells and therefore in keratinocytes. This supports the results of chapter 2 and 3 and 
confirms that keratinocytes are likely to be the primary target for estrogen action in the 
skin in terms of increasing keratin production. Furthermore, we see no evidence for 
increased rates of proliferation of HaCaTs exposed to estrogen, indicating that the 
observed increase in keratin produced on the western blot is due to a net increase in 
keratin per cell. This is again corroborates our data from chapters 2 and 3 and suggests 
that keratinocytes respond to estriol by increasing keratin production per cell and not by 
increasing proliferation. In alignment with our human studies reported in Chapter 3, it 
appears to confer this action on keratinocytes by a receptor-mediated mechanism to 
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modulate the expression of genes involved in keratinocyte differentiation. We observed 
marked differences in the expression of terminal differentiation markers in HaCaT cells 
exposed to estrogen that were at odds with what we observed to estrogen exposed 
foreskins in vivo. Obviously, HaCaT cell monoculture can never hope to fully recapitulate 
the complexity of signaling events and intercellular signaling seen in skin in vivo and 
suggests that extrapolation of findings back to in vitro models must be done with caution. 
Nevertheless, this is the first study to document the ability of estriol to accelerate keratin 
production and differentiation in HaCaT cells. Furthermore, acceleration of keratin 
production, without altering cellular proliferation rates provides an ideal way to increase 
keratinization without an increased risk of the cells becoming tumorigenic in vivo and/or 
in vitro.    
 
HaCaT cells have previously been reported to be a great model for studying keratinocyte 
differentiation of normal skin, however, our studies suggests that estrogen responses in 
mucosal skin may be quite different. More fundamental studies are needed to fully 
understand the production of keratins in the foreskin mucosa and to identify the potential 
targets of activated estrogen receptors in these pathways. If time was permitted, I would 
have liked to perform ER chromatin immunoprecipitation (ChIP) alongside transcriptome 
sequencing of HaCaT cells in treated and untreated cohorts to examine more global 
changes in expression as a result of estrogen exposure, as well as the likely direct targets 
of activated ERs.
  
 
  
 
 
 
Chapter 5 
Summary and Future Directions
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Over 2 million people became infected with HIV in 2013 alone, and nearly as many died 
from complications of AIDS [207]. These devastating diseases plague just about every 
country in the world. Although the latest reports reveal that rates of new infection are 
declining, about 35 million people are currently living with HIV [207, 208]. Each one of 
these people, has the potential to transmit the disease. In 2013, men accounted for about 
53% of new infections globally [208]. Reducing HIV transmission in populations where it 
remains a major health threat hinges on developing or improving safe and effective 
treatments that are reliable, cost-effective, and available to all who seek them. In spite of 
the success and availability of current HIV intervention strategies to prevent, manage, 
and/or treat infections, HIV continues to disproportionately affect men in certain sub-
populations. Two of the best lines of defense against HIV in sexually active males, 
condoms and circumcision, are effective because they enhance the barrier between the 
penis and its external environment.  
 
Estriol, a naturally occurring compound, is currently being used to treat a number of 
conditions, including inflammatory conditions that compromise the protective barrier of 
the male and female reproductive tracts [105, 209].  This weak hormone has also been 
shown to accelerate wound healing and induce keratinization [12, 210]. The long term 
research goal of this project is to test and implement topical estriol as a preventive therapy 
that can be used to significantly reduce the incidence of new HIV infections in 
uncircumcised men. Using data generated from a phase I clinical trial, our objective was 
to determine how topical estriol affects the epithelium of the human foreskin, thereby 
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defining the effect of treatment on epithelial and target cell physiology. Topical estriol 
offers the advantage of being a ready-made, FDA approved treatment that may be a 
useful medical adjunct to condoms and circumcision for reducing HIV transmission.  
 
Through extensive histology in Chapter 2, we provided the first report of direct evidence 
demonstrating that estriol is capable of inducing keratinization of the inner foreskin 
resulting in increased thickness of the stratum corneum. Furthermore, this effect was 
exerted without affecting the quantity or position of the underlying primary immune cells. 
Our findings are significant because we observed this effect using our highest dose of 
500 μg estriol. This dose is half of what is currently prescribed clinically to treat 
menopausal symptoms and phimosis in males. It is possible that an even lower dose may 
also be beneficial, however, this was not the case for our small number of participants. 
Overall, the positive benefits of estriol treatment on the inner foreskin provides a 
foundation to propose a phase 2 clinical trial to further investigate this treatment regimen 
for reducing HIV infections in uncircumcised males.  
 
In Chapter 3, expression profiling of genes and proteins involved in formation of the 
stratum corneum shed light on the mechanism by which exogenous estriol could mediate 
increased viral resistance of the mucosal epithelium. To our knowledge, this is the first 
transcriptomic analysis to assess the effect of estriol on the foreskin. We have shown that 
estriol induces terminal differentiation of epidermal keratinocytes, producing enhanced 
keratinization of the stratum corneum.  The pathway by which estriol exerts this effect 
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was not limited to keratin protein production, but rather a more complex epidermal 
terminal differentiation system, including the presence of inflammatory and immune 
response markers. Our small sample size makes it difficult to ascertain the biological 
relevance of what we have observed. More work is needed to examine estrogen’s effect 
on each marker. In addition to proving estriol’s ability to regulate stratum corneum 
development, we also sought alternate means to target keratinization without the use of 
hormones. Our analysis suggest that an immune/inflammatory response characterized 
by up-regulation of cytokines may not negatively affect the integrity of the stratum 
corneum. However, cytokines can interfere with differentiation, therefore, its beneficial 
role needs to be explored further. We also observed an up-regulation in late epidermal 
crosslinking genes, thus identifying other compounds that can increase the production of 
crosslinking proteins that may also be beneficial. ChIP-seq can be used to study all 
estrogen targets identified.   
 
Establishing HaCaT cells as a sufficient model for characterizing, in the absence of 
compounding factors, estriol’s ability to enhance or inhibit cellular proliferation and 
differentiation processes in keratinocytes was of paramount importance. Our findings in 
Chapter 4 suggests that HaCaTs are a readily available platform that can enable us to 
improve our understanding of the dynamics involved in the formation of the stratum 
corneum, however, the findings in our data set suggest that they may not be suitable as 
a stand-alone model for mucosal tissues. Treatment of HaCaT cells with estriol promotes 
keratinocyte differentiation corroborating our results in Chapter 3. However, differential 
expression of filaggrin and involucrin as compared to our in vivo results may suggest that 
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the presence of other estrogen responsive cells in the epidermis may alter signaling of 
these proteins. Furthermore, HaCaT cells exhibit aneuploidy with duplicated 
chromosomes which could contribute to the differential gene expression observed. 
Although estriol’s stimulation of mucosal skin in vivo and normal skin in vitro result in 
contrasting differentiation patterns, the end result could be the same: increased thickness 
of the stratum corneum. To establish biological relevance, all results generated from the 
HaCaT data will need to be re-evaluated in vivo.  
 
The limitations of our study strongly demonstrate the need for more insight into basic 
foreskin biology before our data can be fully interpreted for biological relevance. Overall, 
the results reported in this thesis strongly support our hypothesis that estriol can be used 
as a potent stimulator of keratinization in the foreskin. A phase 2 clinical trial is warranted 
to assess the hormone’s effect on a larger sample size. Although, we observed an up-
regulation in the expression of potentially negative genes, CCR5 and GAGE, there was 
a lack of evidence correlating their expression with increased risk of HIV infectivity or 
cancer susceptibility. Nevertheless, it is absolutely necessary to explore their role in our 
data set before proceeding with large scale treatments.  
 
Data obtained from these studies will allow us to define how the effects of exogenous 
estrogen mediate increased viral resistance of the mucosal epithelium at the histological 
and protein level. Previous studies have reported that human foreskin grown in tissue 
culture is susceptible to HIV-1 [72, 211]. Furthermore, migratory cells originating from the 
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HIV-1 treated explants are able to disseminate the virus [211]. Both studies also suggest 
that the inner foreskin is highly susceptible to infection. Our studies have shown that 
estrogen increases the thickness of the stratum corneum on the inner foreskin, potentially 
limiting exposure of the Langerhans cells to viruses, and therefore may reduce HIV 
infectivity rates. However, no studies have been performed to evaluate the implications 
of protection through estrogen treatment for males. Future aims of this study could assess 
the effects of topical estrogen on the inner foreskin in the presence of HIV-1 using foreskin 
explants as an in vivo model system. 
 
Comparative studies in a primate model system would yield the best results for 
determining biological relevance. We would like to determine the suitability of the Rhesus 
Macaque as a model in which to define efficacy of estriol treatment in vivo in the presence 
of simian immunodeficiency virus (SIV). While the protective effect of estrogen treatment 
on the epithelium has been clearly demonstrated in the vagina of the Rhesus Macaque, 
it is necessary to investigate if it is equally effective in the foreskin. The phallus or penis 
is one of the most variable structures throughout mammals. However, the rhesus monkey 
penis is similar in morphology to that of humans, but has a comparatively elongated 
foreskin covering the glans penis in the flaccid state. As in humans, this is retracted 
exposing a large inner foreskin surface during intercourse. Therefore, preliminary efficacy 
trials, to directly assess the effectiveness of increased keratin in increasing resistance to 
SIV infection, could be performed in the Rhesus monkey model system. We will determine 
if the Rhesus monkey foreskin is sufficiently similar to humans in histology and 
immunology to be a suitable model to test efficacy of the estriol treatment in clinical trials. 
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If the histology and immunology of the monkey and human penises are suitably similar, it 
would support the use of the Rhesus monkey to investigate the efficacy of the treatment 
and suitability of the intervention for human clinical trials. In the event that the rhesus 
macaque tissues do not compare favorably to the human foreskin samples, in vitro 
studies using human explant penile tissues can be grown in culture and treated with estriol 
to determine its effect. 
 
The skin is vital for life as it is key in keeping moisture in and preventing entrance of 
pathogens. The penile skin of uncircumcised men has a thin stratum corneum and viral 
target cells are present in the epithelium. As a result, this population of men are at a 
higher risk of acquiring sexually transmitted diseases, such as HIV and HPV, compared 
to their circumcised counterparts. Estriol is capable of enhancing the stratum corneum 
specifically through up-regulation of differentiation, thus it is a promising medical adjunct 
for reducing HIV transmission in uncircumcised men. The results reported in this thesis 
can have a global impact by providing a safe, non-invasive method for controlling the 
spread of HIV in developing countries and may aid in controlling the spread of HPV in 
developed countries. As I stated in the introduction to this thesis, “prevention is always 
better than a cure.”  
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